scln stock quote  sciclone pharmaceuticals inc price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  scln sciclone pharmaceuticals inc quote  summary data     unch unch get scln alerts delayed  data as of jul    et    find a broker to begin trading scln now exchangenasdaq industry health care community rating view    scln real time scln     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock       year target todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple  forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec sciclone pharmaceuticals inc nasdaq scln is a united states usheadquartered chinafocused specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology infectious diseases and cardiovascular disorders we are focused on continuing to grow our revenue and profitability our business and corporate strategy is focused primarily on the peoples republic of china china or prc where we have built a solid reputation and established a strong brand through many years of experience marketing our lead product zadaxin thymalfasin in addition we have an established business model with large pharmaceutical partners to promote and sell products we believe our sales and marketing strengths position us to benefit from the longterm expansion of the pharmaceutical market in china   more    risk grade where does scln fit in the risk graph news for scln company news for june     am  zackscom risk arbitrage today yahoo pandora and an ma fund that has  in one stock   am  seeking alpha gainers  losers of june  anab ino scln nlnk juno   am  rtt news buzzus stocks on the movenordstrom alibaba sciclone valeant   pm  reuters sciclone pharmaceuticals moves notably higher on buyout   pm  rtt news  subscribe more scln news  commentary read scln press releases consensus recommendation analyst info annual eps est  quarterly eps est peg ratio na mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex sciclone pharmaceuticals inc nasdaqscln quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancesciclone pharmaceuticals incnasdaqsclnadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   sciclone pharmaceuticals inc  public nasdaqscln   watch this stock      realtime   am edt nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg  mkt cap m pe  divyield      eps  shares m beta  inst own  news relevance date all news for sciclone pharmaceuticals inc » subscribe advertisement events add scln to my calendars aug   q  sciclone pharmaceuticals inc earnings release estimated  am edt  jun   sciclone pharmaceuticals inc annual shareholders meeting estimated jun   sciclone pharmaceuticals inc annual shareholders meeting may   q  sciclone pharmaceuticals inc earnings call  may   q  sciclone pharmaceuticals inc earnings release more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  tower ln ste foster city ca united states  map phone fax website links httpwwwsciclonecom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry pharmaceuticals  nec more from factset » description sciclone pharmaceuticals inc is a pharmaceutical company the companys product portfolio of therapies includes oncology infectious diseases and cardiovascular disorders the companys business is focused primarily in the peoples republic of china the company operates in two segments china and the rest of the world including its operations in the united states and hong kong the companys lead product zadaxin thymalfasin is approved in over  countries which is used for the treatment of hepatitis b virus hbv hepatitis c virus hcv and certain cancers according to the local regulatory approvals and for use as an immune system enhancer in addition to zadaxin sciclone markets seven partnered and inlicensed products in china the company sells zadaxin in various international markets through its subsidiary sciclone pharmaceuticals international ltd spil its development portfolio includes angiomax loramyc neucardin vibativ and cleviprex more from reuters » officers and directors jon s saxe independent chairman of the board age  bio  compensation   reuters friedhelm blobel phd president chief executive officer director age  bio  compensation   reuters wilson w cheung chief financial officer senior vice president  finance secretary age  bio  compensation   reuters hong zhao chief executive officer  china operations age  bio  compensation   reuters raymond anthony low cpa vice president  finance controller age  bio  compensation   reuters lan xie cpa vice president  finance china chief financial officer age  bio  compensation   reuters nancy t chang phd independent director age  bio  compensation   reuters richard james hawkins independent director age  bio  compensation   reuters anthony gregg lapointe independent director age  bio  compensation   reuters simon li independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service sciclone pharmaceuticals inc nasdaqscln contact us  site map   english news  events june    sciclone enters into definitive merger agreement to be acquired by consortium led by gl capital may    sciclone reports first quarter  financial results may    sciclone pharmaceuticals to report first quarter  financial results on may   login   sciclone pharmaceuticals inc all rights reserved please read our disclaimer terms of use  notes regarding forward looking statements 。。    sciclone pharmaceuticals inc marketed and development products contact us  site map   english product portfolio   therapeutic area product status partner marketed portfolio “…its not enough anymore just to have generics that might work for the immediate future…but beyond that you need to have differentiated products if you want to remain or become a player in the pharmaceutical market” dr blobel on evolving china pharma market   bioworld today november   hbv hcv cancer immune system enhancer sepsis zadaxin marketed since  sciclone proprietary oncology holoxan mesna endoxan methotrexate farlutal estracyt dc bead marketed marketed marketed marketed marketed marketed marketed baxter baxter baxter pfizer pfizer pfizer btg sciclone is building a portfolio of highquality differentiated branded products with established pedigrees as safe and effective treatments in major therapeutic areas relevant to the chinese patient population such as oncology cardiovascular disease and infectious disease each of these products exemplifies the attributes that are wellsuited for the evolving china pharma market our marketed product portfolio is led by our proprietary flagship product the immunostimulatory agent zadaxin® newly launched novel oncology product dc bead® and a lineup of standardofcare oncology products   therapeutic area product status partner development portfolio oncology   sgx abtl pt phase  early clinical phase  soligenix inc ability pharma phosplatin therapeutics cardiovascular angiomax neucardin cleviprex nda in review phase  cta application filed the medicines co zensun the medicines co antiinfective loramyc vibativ nda in preparation cta application planning onxeo theravance biopharma our development portfolio includes potential therapeutic class leaders approved in western markets such as the cardiovascular drugs angiomax® and neucardin™ and the antibiotic vibativ® which could move through the regulatory process as midterm market opportunities we have built this attractive portfolio through targeted and successful partnering with leading pharmaceutical and biotechnology companies including multinational corporations and innovative biopharma companies in the us europe and china login   sciclone pharmaceuticals inc all rights reserved please read our disclaimer terms of use  notes regarding forward looking statements 。。    sciclone pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of sciclone pharmaceuticals inc snapshot people company overview sciclone pharmaceuticals inc a specialty pharmaceutical company provides therapies for oncology infectious diseases and cardiovascular disorders in the people’s republic of china the united states and hong kong its lead product is zadaxin which is used for the treatment of hepatitis b and hepatitis c viruses and certain cancers as well as for use as an immune system enhancer in addition the company focuses on developing zadaxin for the treatment of sepsis sciclone pharmaceuticals inc markets and sells zadaxin through distribution arrangements local importers and distributors it also markets and distributes products such as dc bead holoxan mesna endoxan methotrexate  sciclone pharmaceuticals inc a specialty pharmaceutical company provides therapies for oncology infectious diseases and cardiovascular disorders in the people’s republic of china the united states and hong kong its lead product is zadaxin which is used for the treatment of hepatitis b and hepatitis c viruses and certain cancers as well as for use as an immune system enhancer in addition the company focuses on developing zadaxin for the treatment of sepsis sciclone pharmaceuticals inc markets and sells zadaxin through distribution arrangements local importers and distributors it also markets and distributes products such as dc bead holoxan mesna endoxan methotrexate estracyt farlutal neucardin angiomax and cleviprex the company has a strategic partnership with the medicines company to promote angiomax bivalirudin and cleviprex clevidipine sciclone pharmaceuticals inc was founded in  and is headquartered in foster city california detailed description  tower lanesuite foster city ca united statesfounded in  employees phone  fax  wwwsciclonecom key executives for sciclone pharmaceuticals inc dr friedhelm blobel phd chief executive officer president and executive director age  total annual compensation k mr wilson w cheung chief financial officer and senior vice president of finance age  total annual compensation k mr hong zhao chief executive officer of china operations age  total annual compensation k ms lan xie vice president of finance and chief financial officer of china operations age  total annual compensation k compensation as of fiscal year  sciclone pharmaceuticals inc key developments sciclone pharmaceuticals inc announces election of directors jun   sciclone pharmaceuticals inc elected jon s saxe friedhelm blobel phd and simon li as directors at the annual meeting of stockholders of the company held on june   sciclone pharmaceuticals inc reports unaudited consolidated earnings results for the first quarter ended march   may   sciclone pharmaceuticals inc reported unaudited consolidated earnings results for the first quarter ended march   the companys revenues in the first quarter of  were  million a  million or  increase compared to  million for the same period in  on a gaap basis the company reported net income in the first quarter of  of  million or  and  per share on a basic and diluted basis respectively compared to net income of approximately  million or  and  per share on a basic and diluted basis respectively for the same period in  the companys nongaap net income in the first quarter of  was  million or  and  per share on a basic and diluted basis respectively compared with nongaap net income of  million or  and  per share on a basic and diluted basis respectively for the same period of the prior year both gaap and nongaap net income were favorably impacted by the additional revenue recognition for zadaxin fourth quarter sales and a chinese government subsidy in the first quarter of  income from operations was  million compared with  million a year ago income before provision for income tax was  million compared with  million a year ago sciclone pharmaceuticals inc announces changes in bylaws may   on may   the board of directors of sciclone pharmaceuticals inc approved amendments to the companys amended and restated bylaws to a add a new provision to the companys bylaws that designates the state and federal courts located within the state of delaware as the sole and exclusive forum for certain legal actions unless the company consents in writing to the selection of an alternative forum the bylaws became effective immediately similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target mergeracquisition november    private placement september   soligenix inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sciclone pharmaceuticals inc please visit wwwsciclonecom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close sciclone pharmaceuticals inc  investors contact us  site map   english investors sciclone pharmaceuticals is a revenuegenerating specialty pharmaceutical company with a substantial commercial business in china and a product portfolio spanning major therapeutic markets including oncology infectious diseases and cardiovascular disorders sciclone’s proprietary lead product zadaxin® thymalfasin is approved in over  countries and may be used for the treatment of hepatitis b hbv hepatitis c hcv and certain cancers and as an immune system enhancer according to the local regulatory approvals the company has successfully inlicensed and commercialized products with the potential to become future market leaders and to drive the companys longterm growth including dc bead® a novel treatment for liver cancer through its promotion business with pharmaceutical partners sciclone also markets multiple branded products in china which are therapeutically differentiated sciclone is a publiclyheld corporation based in foster city california and trades on the nasdaq global select market under the symbol scln  sciclone corporate presentation june  nasdaq scln     day high  day low   volume      am et jul   delayed  min by esignal  mo  mo  yr may    pm et q  sciclone pharmaceuticals inc earnings press room jun   sciclone enters into definitive merger agreement to be acquired by consortium led by gl capital may   sciclone reports first quarter  financial results view all press room » calendar of events may   at  pm et q  sciclone pharmaceuticals inc earnings apr   at  pm et th annual needham healthcare conference view all calendar of events » email alerts email alerts snapshot snapshot rss rss print print email email search search   sciclone pharmaceuticals inc all rights reserved please read our disclaimer terms of use  notes regarding forward looking statements 。。    microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft scln key statistics  sciclone pharmaceuticals inc financial ratios  marketwatch bulletin investor alert london markets close in currencies futures metals stocks expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close sciclone pharmaceuticals inc nasdaq scln go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus sciclone pharmaceuticals inc market open  real time quotes jul    am scln quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description sciclone pharmaceuticals inc is a pharmaceutical company it engages in the development of therapeutics treatment for oncology infectious diseases and cardiovascular disorders its product includes zadaxin holoxan mesna endoxan farlutal methotrexate estracyt dc bead angiomax neucardin c sciclone pharmaceuticals inc is a pharmaceutical company it engages in the development of therapeutics treatment for oncology infectious diseases and cardiovascular disorders its product includes zadaxin holoxan mesna endoxan farlutal methotrexate estracyt dc bead angiomax neucardin cleviprex loramyc and vibativ the company was founded in  and is headquartered in foster city ca valuation pe current  pe ratio with extraordinary items  pe ratio without extraordinary items  price to sales ratio  price to book ratio  price to cash flow ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title dr friedhelm blobel   president chief executive officer  director mr waishun cheung   chief financial officer  senior vpfinance mr carey chern   secretary  chief compliance officer ms lan xie   cfochina operations  vice presidentfinance mr hong zhao   chief executive officerchina operations insider actions – purchase – sale  – number of transactions  date name shares transaction value  friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   waishun cheung cfo  senior vp finance    disposition at  per share   waishun cheung cfo  senior vp finance    disposition at  per share   waishun cheung cfo  senior vp finance    disposition at  per share   lan xie vp finance china cfo    disposition at  per share   hong zhao ceo china operations    disposition at  per share   hong zhao ceo china operations    disposition at  per share   hong zhao ceo china operations    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   raymond anthony low vp finance  controller    derivativenonderivative trans at  per share   waishun cheung cfo  senior vp finance    derivativenonderivative trans at  per share   waishun cheung cfo  senior vp finance    derivativenonderivative trans at  per share   waishun cheung cfo  senior vp finance    derivativenonderivative trans at  per share   lan xie vp finance china cfo    derivativenonderivative trans at  per share   hong zhao ceo china operations    derivativenonderivative trans at  per share   hong zhao ceo china operations    derivativenonderivative trans at  per share   hong zhao ceo china operations    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share   friedhelm blobel president  ceo director    disposition at  per share   friedhelm blobel president  ceo director    derivativenonderivative trans at  per share  newslatestcompanyusscln marketwatch news on scln sciclone pharmaceuticals stock tumbles after ending discussions with acquirers  am july    tomi kilgore nasdaq nails the day average lifts from support  am june    michael ashbaugh sciclone to restate results due to china errors  pm feb    marketwatchcom monday’s biggest gaining and declining stocks  pm aug    marketwatch updates advisories and surprises  pm aug    marketwatch sciclone jumps  in wake of earnings report  pm aug    val brickates kennedy sciclone up  after earnings  am aug    val brickates kennedy updates advisories and surprises  pm march    marketwatch sciclone soars  on earnings report  pm march    val brickates kennedy stocks to watch tuesday armstrong world copart  am march    marketwatch sciclone pharma to buy back up to m stock  am oct    marketwatchcom japanese drug stocks rebound  pm march    val brickates kennedy thursday’s biggest gainers and decliners  pm dec    kate gibson motorola among active afterhours stocks  pm dec    rex crum tuesdays biggest gaining and declining stocks  pm aug    marketwatch sciclone synta lead decliners  pm aug    val brickates kennedy sciclone tumbles on sec probe  am aug    val brickates kennedy fridays biggest gaining and declining stocks  pm april    kate gibson sciclone gentium rexahn in spotlight  pm april    val brickates kennedy sciclone rallies on upgrade drug indices diverge  am april    val brickates kennedy loading more headlines newsnonmarketwatchcompanyusscln other news on scln company news for june    am june    zackscom sciclone pharma to be acquired by chinese consortium for m shares up  premarket  am june    seeking alpha stonepine capital management llc buys viveve medical inc avadel pharmaceuticals plc   pm may    gurufocuscom sciclone pharmaceuticals scln ceo friedhelm blobel on q  results  earnings call transcript  pm may    seeking alpha q sciclone pharmaceuticals inc  pm may    edgar online  edg  q k stonepine capital management llc buys recro pharma sciclone pharmaceuticals novelion   pm march    gurufocuscom sciclone pharmaceuticals scln ceo friedhelm blobel on q  results  earnings call transcript  pm march    seeking alpha sciclone pharmaceuticals beyond the death of a sales process  pm feb    seeking alpha adds and drops from the nasdaq biotech index  pm dec    seeking alpha week in review weeks china life science deals total  million  am nov    seeking alpha sciclone pharmaceuticals scln ceo friedhelm blobel on q  results  earnings call transcript  am nov    seeking alpha q sciclone pharmaceuticals inc  pm nov    edgar online  edg  q k valuation dashboard healthcare  update  am nov    seeking alpha week in review big week for crossborder life science deals  am oct    seeking alpha sciclone advances clinical pipeline for china pharma market  am sept    seeking alpha week in review chinas luxin invests in  million funding for intarcias longterm diabetes device  am sept    seeking alpha soligenix and sciclone ink dusquetide development deal in asia  pm sept    seeking alpha valuation dashboard healthcare  update  pm sept    seeking alpha sciclone pharmaceuticals inc scln president  ceo friedhelm blobel sold  million of stocks  pm aug    gurufocuscom are high composite ratings an automatic buy signal no heres why  am aug    investors business daily loading more headlines at a glance sciclone pharmaceuticals inc  tower lane suite  foster city california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for scln newspressreleasecompanyusscln press releases on scln lifshitzmiller llp announces investigation of ari network services inc dupont fabros technology inc nexvet biopharma public limited company parexel international corporation rice energy inc and sciclone pharmaceuticals inc  pm july    pr newswire  prf daily technical summary reports on drug makers stocks  apricus biosciences durect sucampo pharma and sciclone pharma  am june    pr newswire  prf shareholder alert brower piven commences an investigation into the proposed sale of sciclone pharmaceuticals inc and encourages investors to contact the firm for additional information  pm june    businesswire  bzx sciclone pharmaceuticals inc shareholder alert rigrodsky  long pa announces investigation of buyout  pm june    businesswire  bzx shareholder alert levi  korsinsky llp announces an investigation concerning whether the sale of sciclone pharmaceuticals inc to a consortium is fair to shareholders – scln  am june    businesswire  bzx weisslaw llp the proposed acquisition of sciclone pharmaceuticals inc may not be in the best interest of scln shareholders  pm june    pr newswire  prf sciclone enters into definitive merger agreement to be acquired by consortium led by gl capital  am june    pr newswire  prf what biotech offers a better riskreward profile than soligenix sngx in our view none  am june    accesswire sciclone reports first quarter  financial results  pm may    pr newswire  prf sciclone pharmaceuticals to report first quarter  financial results on may    am may    pr newswire  prf sciclone to present at needham healthcare conference on april    am march    pr newswire  prf how these drug makers stocks are faring  orexigen therapeutics united therapeutics durect and sciclone pharma  am march    pr newswire  prf sciclone reports  financial results and  outlook  am march    pr newswire  prf sciclone pharmaceuticals partnering deals and alliances  to   pm feb    pr newswire  prf sciclone pharmaceuticals to report fourth quarter and full year  financial results on march    am feb    pr newswire  prf healthcare stocks under scanner  aerie pharma gw pharma retrophin and sciclone pharma  am feb    pr newswire  prf sciclone to present at bio ceo  investor conference on february    am feb    pr newswire  prf research reports initiation on drug makers stocks  amphastar pharma united therapeutics mei pharma and sciclone pharma  am nov    pr newswire  prf sciclone confirms receipt of unsolicited proposal from gl capital and abg management  pm nov    pr newswire  prf sciclone reports third quarter  financial results  pm nov    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest awhat is an ico aone way you’re paying creditcard fees even if you don’t have a card astock market edges lower on track for weekly losses aoil sets sights on biggest weekly gain of the year aupdate invisalign maker align stocks surge  after earnings blow past estimates aairbus to sell plant holdings to motorola aamerican airlines profit falls unit revenue gains achevron swings to profit as charges shrink asears canadas biggest shareholders call off bid aredfins stock debuts  above its ipo price atime for gop to face reality everybody is going to have health insurance abp earnings what to expect aexxon chevron post strong profits achina penalizes nine banks for forex violations aredfins stock opens at  or  above  ipo price aeurope’s refugee crisis won’t be solved in a distant court awhat trump could do to make obamacare ‘implode’ afoxconn’s history of broken promises casts a shadow on wisconsin news ahere’s something that can improve your memory — and help you sleep a million or  a month which would you choose loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  sciclone pharmaceuticals inc  press room contact us  site map   english press room year all years                    sort by date descending date ascending update   press room   date title view jun   sciclone enters into definitive merger agreement to be acquired by consortium led by gl capital foster city calif june   prnewswire  sciclone pharmaceuticals inc nasdaq scln the company or sciclone and a consortium consisting of entities affiliated with gl capital management gp limited gl capital bank of china group investment limited bocgi cdh investments ascendent capital partners and boying collectively pdf may   sciclone reports first quarter  financial results foster city calif may   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended march   revenues in the first quarter  sciclone reported revenues of  million compared to  million for the same period in  gaap diluted eps in the first q pdf may   sciclone pharmaceuticals to report first quarter  financial results on may   foster city calif may   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the first quarter  on wednesday may   sciclone will host a conference call and webcast to provide a business update at  pm et  pm pt that day the call will be hosted by  pdf mar   sciclone to present at needham healthcare conference on april   foster city calif march   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the th annual needham healthcare conference at  pm et on tuesday april   at the westin ny grand central hotel in new  pdf mar   sciclone reports  financial results and  outlook foster city calif march   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the fourth quarter and year ended december   revenues in the fourth quarter of  sciclone reported revenues of  million compared to  million for the same period in  revenues fo pdf feb   sciclone pharmaceuticals to report fourth quarter and full year  financial results on march   foster city calif feb   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the fourth quarter and full year  on monday march   sciclone will host a conference call and webcast to provide a business update at  am et  am pt that day the call wil pdf feb   sciclone to present at bio ceo  investor conference on february   foster city calif feb   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the th annual bio ceo  investor conference at  pm et on monday february   at the waldorf astoria hotel in new  pdf nov   sciclone confirms receipt of unsolicited proposal from gl capital and abg management foster city calif nov   prnewswire  sciclone pharmaceuticals inc nasdaq scln sciclone today confirmed that it has received an unsolicited nonbinding proposal from a consortium led by gl capital management gp limited and abg management limited to acquire all of the outstanding shares of sciclone not already owned by the cons pdf nov   sciclone reports third quarter  financial results foster city calif nov   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended september   revenues in the third quarter of  sciclone reported revenues of  million compared to  million for the same period in  gaap diluted eps in pdf oct   sciclone pharmaceuticals to report third quarter  financial results on november   foster city calif oct   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the third quarter  on wednesday november   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call  pdf sep   sciclone announces progress in advancing clinical pipeline for china pharmaceuticals market foster city calif sept   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced two important achievements in advancing the companys clinical pipeline and development portfolio in greater china the first patient has been treated in the phase  trial of zadaxin® in sepsis a lifethreatening infectious diseas pdf sep   soligenix and sciclone establish regional licensing agreement for sgx a novel product candidate for oral mucositis princeton nj and foster city calif sept   prnewswire  soligenix inc otcqb sngx a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need and sciclone pharmaceuticals inc nasdaq scln a usbased chinafocused specialty pharmaceut pdf sep   sciclone to present at two investor conferences in september  foster city calif sept   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that the company will present a corporate overview and business update at two investor conferences in september  friedhelm blobel phd chief executive officer will present at the rodman  renshaw th annual global  pdf aug   sciclone reports second quarter  financial results foster city calif aug   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended june     revenues in the second quarter of  sciclone reported revenues of  million compared to  million for the same period in  gaap diluted ep pdf jul   sciclone pharmaceuticals to report second quarter  financial results on august   foster city calif july   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the second quarter  on tuesday august   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call wil pdf jul   sciclone provides update on strategic review process foster city calif july   prnewswire  sciclone pharmaceuticals inc nasdaq scln today provided an update on part of the strategic review process that was previously announced in february  the company announced that it is no longer continuing active discussions with potential acquirers which were undertaken as part of its strat pdf may   sciclone reports first quarter  financial results foster city calif may   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended march   revenues in the first quarter  sciclone reported revenues of  million compared to  million for the same period in  gaap diluted eps in the fi pdf apr   sciclone pharmaceuticals to report first quarter  financial results on may   foster city calif april   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the first quarter  on tuesday may   sciclone will host a conference call and webcast to provide a business and product update at  am et  am pt that day the call will  pdf mar   sciclone to present at needham healthcare conference on april   foster city calif march   prnewswire sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the th annual needham healthcare conference at  am et on wednesday april   at the westin grand central hotel in new y pdf mar   sciclone reports  financial results foster city calif march   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter and year ended december   revenues revenues for the full year  were  million compared to  million for the full year of  in the fourth quarter of  revenues w pdf feb   sciclone pharmaceuticals to report  financial results on march   foster city calif feb   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the fourth quarter and full year  on thursday march   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that da pdf feb   sciclone announces final resolution with the securities and exchange commission and the department of justice foster city calif feb   prnewswire  sciclone pharmaceuticals inc nasdaq scln the company today announced it has entered into a settlement agreement with the united states securities and exchange commission sec fully resolving the secs investigation into possible violations of the foreign corrupt practices act fcpa  unde pdf jan   sciclone to present at bio ceo  investor conference on february   foster city calif jan   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the th annual bio ceo  investor conference at  am et on tuesday february   at the waldorf astoria hotel in new pdf jan   sciclone announces preliminary  revenue foster city calif jan   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced its preliminary  revenue results and that it has achieved its revenue expectations for  for  the company expects  sales revenues of between  and  million which are at the high end of the guidance o pdf dec   sciclone to pursue development of sgx in china following soligenix report of positive phase  preliminary results in oral mucositis foster city calif dec   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced plans to pursue development and registration of sgx in the greater china market for the treatment of oral mucositis sgx is being developed by soligenix inc otcqb sngx which recently reported positive preliminary results fro pdf nov   sciclone to present at th annual piper jaffray healthcare conference on december   foster city calif nov   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the th annual piper jaffray healthcare conference at  am et on wednesday december   at the new york palace hotel pdf nov   sciclone reports third quarter  financial results foster city calif nov   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended september   revenues in the third quarter of  sciclone reported revenues of  million compared to  million for the same period in   gaap diluted eps i pdf nov   sciclone to present at boston biotech nynj ceo conference on november th foster city calif nov   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will participate in a panel discussion at the boston biotech conferences bbc nynj ceo conference on november th at the apella in new york city the conference will foc pdf oct   sciclone pharmaceuticals to report financial results for the third quarter  on november th foster city calif oct   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the third quarter  on monday november   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call wil pdf sep   sciclone to present at  aegis capital growth conference on october th foster city calif sept   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the  aegis capital growth conference at  am pt on friday october   at the encore at wynn las vegas   t pdf aug   sciclone to present at two investor conferences on september   foster city calif aug   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at two investor conferences on september   in new york city nd annual newsmakers in the biotech industry pr pdf aug   sciclone reports second quarter  financial results foster city calif aug   prnewswire  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended june     revenues in the second quarter  sciclone reported revenues of  million compared to  million for the same period in  gaap diluted eps pdf jul   sciclone pharmaceuticals to report financial results for the second quarter  on august th foster city calif july   prnewswire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the second quarter  on monday august   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call wil pdf may   sciclone pharmaceuticals and theravance biopharma enter into development and commercialization agreement for vibativr telavancin in china foster city ca and george town grand cayman  marketwired    sciclone pharmaceuticals nasdaq scln sciclone a usbased chinafocused specialty pharmaceutical company and theravance biopharma inc nasdaq tbph theravance biopharma through an affiliate today announced they have entered into a development and  pdf may   sciclone to present at jefferies  global healthcare conference on june   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the jefferies  global healthcare conference at  am et on wednesday june   in new york city to access pdf may   sciclone reports first quarter  financial results foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the quarter ended march   revenues in the first quarter  sciclone reported revenues of  million compared to  million for the same period in   pdf apr   sciclone pharmaceuticals to report financial results for the first quarter  on may th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the first quarter  on monday may   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call will b pdf apr   sciclone to present at needham healthcare conference on april   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the th annual needham healthcare conference at  pm et on tuesday april   at the westin grand central hotel in new yo pdf mar   sciclone to present at investor and partnering conferences in china foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at upcoming investor and partnering conferences taking place in china the conferences are as follows  pdf mar   sciclone reports  financial results and  outlook foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the fourth quarter and year ended december   revenues in the fourth quarter  sciclone reported revenues of  million compared to  million for the same period i pdf feb   sciclone pharmaceuticals to report financial results for the fourth quarter and full year  on march th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the fourth quarter and full year  on wednesday march   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that pdf jan   sciclone to present at bio ceo  investor conference on february   at  am et foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the th annual bio ceo  investor conference at  am et on monday february   at the waldorf astoria hotel in ne pdf jan   sciclone provides  financial update and  revenue guidance foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reconfirmed its anticipated yearend  revenue and nongaap earnings per share eps guidance and provided its anticipated revenue guidance for  as follows for  the company reconfirms ex pdf dec   the medicines company and sciclone pharmaceuticals establish strategic partnership for two cardiovascular products in china sciclone to promote potential hospital market leaders in china angiomax® bivalirudin and cleviprex® clevidipine parsippany nj  foster city califbusiness wire the medicines company nasdaqmdco a global biopharmaceutical company focused on hospital care and scicl pdf nov   sciclone reports financial results for the third quarter  foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the third quarter  revenues revenues in the third quarter of  were  million compared to  million for the same period in  gaap basic eps g pdf nov   sciclone to present at jefferies global healthcare conference on november th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the jefferies global healthcare conference on november   at  pm gmt taking place at the waldorf hilton hotel i pdf oct   sciclone pharmaceuticals to report financial results for the third quarter  on november th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the third quarter  on monday november   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call  pdf sep   sciclone to present at biocentury newsmakers in the biotech industry conference on september   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the  biocentury newsmakers in the biotech industry conference at  am et on friday september   at the millenn pdf sep   sciclone to present at aegis  healthcare  technology conference on september   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the aegis capital corp  healthcare  technology conference at  am pt on thursday september   at the encore at w pdf aug   sciclone and btg announce that dc beadr has been approved by china food and drug administration foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln and its partner btg plc lse btg today announced that the china food and drug administration has approved the registration of dc bead® for the embolization of malignant hypervascularized tumors btg and sciclone previously entered  pdf aug   sciclone reports financial results for the second quarter  foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the second quarter  revenues revenues in the second quarter of  were  million compared to  million for the same period in  gaap basic eps pdf jul   sciclone pharmaceuticals to report financial results for the second quarter  on august th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the second quarter  on monday august   sciclone will host a conference call and webcast to provide a business and product update at  pm et  pm pt that day the call w pdf may   sciclone to present at jefferies  global healthcare conference on june   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the jefferies  global healthcare conference at  am et on tuesday june   in new york city to acce pdf may   sciclone reports financial results for the first quarter  foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the first quarter ended march   revenues revenues for the first quarter  were  million compared to  million for the same period in  on the basis of the com pdf may   sciclone pharmaceuticals to report financial results for the first quarter  on may th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the first quarter  on monday may   sciclone will host a conference call and webcast to provide a business and product update at  am et that day the call will be hosted by f pdf apr   sciclone to present at needham healthcare conference on april   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that wilson w cheung chief financial officer will present a corporate overview and business update at the th needham healthcare conference at  pm et on tuesday april   at the westin ny grand central hotel in new york ci pdf mar   sciclone reports  financial results and  outlook foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the fourth quarter and year ended december   revenues revenues for the full year  were  million compared to  million for the full year of  in the fourth  pdf mar   sciclone pharmaceuticals to report financial results for the fourth quarter and full year  on march th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the fourth quarter and full year  on wednesday march   sciclone will host a conference call and webcast to provide a business and product update at  am et that day the call pdf feb   sciclone appoints charles meng as general counsel and vice president of compliance foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced the appointment of charles meng as general counsel and vice president of compliance effective february   mr meng has more than  years of experience in compliance and legal affairs spanning multinational companies in diverse in pdf feb   sciclone to present at bio ceo  investor conference on february   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the th annual bio ceo  investor conference at  am et on tuesday february   at the waldorf astoria hotel in  pdf jan   sciclone announces transition from pricewaterhousecoopers llp to pricewaterhousecoopers zhong tian llp as independent registered public accounting firm foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that the audit committee of the companys board of directors has appointed pricewaterhousecoopers zhong tian llp pwc china to replace pricewaterhousecoopers llp pwc us as the companys independent registered public accounting fi pdf jan   sciclone provides  financial update and  guidance foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced its anticipated yearend  cash position and provided its initial  revenue guidance as follows the company anticipates  yearend cash and investments to be approximately  million excluding  pdf dec   sciclone to present at oppenheimer healthcare conference on december   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the oppenheimer th annual healthcare conference on tuesday december   at  pm et at the crowne plaza hotel in  pdf nov   sciclone reports financial results for the three and nine months ended september   foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the third quarter and for the nine months ended september   revenues in the third quarter  sciclone reported revenues of  million compared to  million for the  pdf nov   sciclone pharmaceuticals to report financial results for the third quarter  on november th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the third quarter  on tuesday november   sciclone will host a conference call and webcast to provide a business and product update at  am et that day the call will be host pdf sep   sciclone appoints nancy t chang phd to its board of directors foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that nancy t chang phd has been appointed a member of the companys board of directors dr chang has more than  years of experience in the pharmaceutical and biotechnology industry and has successfully developed and commerciali pdf sep   sciclone to present at four investor conferences in september  foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that the company will present a corporate overview and business update at four upcoming investor conferences in september  friedhelm blobel phd chief executive officer will present at the morgan stanley global healthc pdf aug   sciclone reports financial results for the three and six months ended june   and updates  guidance foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the three and six months ended june   and updated guidance for  overall revenues were  million a decrease of  million or  for the first half of  compared to  million  pdf aug   sciclone pharmaceuticals to report financial results for the three and six months ended june   on august th foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report financial results for the three and six months ended june th  on wednesday august   sciclone will host a conference call and webcast to provide a business and product update at  am et that day pdf jul   sciclone appoints wilson w cheung as chief financial officer foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced the appointment of wilson w cheung as chief financial officer and senior vice president finance mr cheung is an experienced senior financial and international accounting executive with broad experience spanning financial management pdf jun   sciclone and taiwan liposome company enter into a licensing agreement for proflowr a novel treatment for peripheral arterial disease for the china market foster city ca and taipei city taiwan  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that the company has entered into an agreement with taiwan liposome company tlc granting sciclone a license and the exclusive rights in china hong kong and macau to promote market distribute and sell proflow pdf may   sciclone to present at jefferies  global healthcare conference foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the jefferies  global healthcare conference on june   at  pm et at the grand hyatt hotel in new york city  pdf may   sciclone reports anticipated financial results for the first quarter  foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today reported its expectations regarding financial results for the quarter ended march   friedhelm blobel phd sciclone chief executive officer commented the accounting treatment for portions of our novamed promotion services pdf may   sciclone and zensun enter into a licensing agreement for novel chronic heart failure drug neucardintm for the china market foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced that the company has entered into an agreement with zensun shanghai science  technology co ltd granting sciclone a license and the exclusive rights in china hong kong and macau to promote market distribute and sell neucardin pdf apr   sciclone appoints pricewaterhousecoopers llp as its independent registered public accounting firm foster city ca  marketwired    sciclone pharmaceuticals inc nasdaq scln today announced the audit committee of the companys board of directors has appointed pricewaterhousecoopers llp pwc as its independent registered public accounting firm effective immediately to perform independent audit services beginning with t pdf apr   sciclone reports  financial results and  outlook foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the fourth quarter and for the year ended december   overall revenues increased  million or  for the full year  to  million compared to  million for the prior year inc pdf apr   sciclone pharmaceuticals to report  financial results and  outlook on april st foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report  financial results and  outlook today monday april   sciclone will host a conference call and webcast to provide a business and product update at  pm et today the call will be hosted by fried pdf mar   sciclone appoints hong zhao as chief executive officer china operations foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced the appointment of hong zhao as chief executive officer china operations mr zhao is an accomplished respected pharmaceutical industry executive with more than  years of experience in leading the commercial operations market expans pdf mar   sciclone provides update on the timing of filing its  annual report on form k foster city ca  marketwire    as previously reported on february   sciclone pharmaceuticals inc nasdaq scln is restating its financial statements for fiscal year  and the first three quarters of fiscal  the company is in the process of completing the restatement of the financials and the companys annual  pdf feb   sciclone to restate financial statements for  and  periods foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that it will be restating its financial statements for each of the first second and third quarters of  and financial statements for each of the second and third quarters of  and for the year ended december   the restate pdf feb   sciclone to present at bio ceo  investor conference on february th foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd chief executive officer will present a corporate overview and business update at the th annual bio ceo  investor conference on tuesday february   at  pm et at the waldorf astoria hotel in new pdf jan   sciclone announces product promotion agreement renewal with key industry parnter sanofi in china foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that it has successfully negotiated renewals of its exclusive product promotion agreement with sanofi for the china market under the terms of the sanofi agreement sciclone through its wholly owned subsidiary novamed ph pdf jan   sciclone announces appointment of simon li to its board of directors foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced the appointment of simon li to its board of directors mr li is an accomplished and respected leader in the pharmaceutical and medical device industries in china and asia and brings to sciclones board more than  years of experience  pdf jan   sciclone provides initial  financial guidance foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced its anticipated  initial revenue earnings per share eps and yearend cash guidance and  yearend cash position as follows the company anticipates  sales revenue of  million   million the com pdf dec   sciclone to present at oppenheimer rd annual healthcare conference on december th foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel chief executive officer will present a corporate overview and business update at the oppenheimer rd annual healthcare conference on december   at  am et at the waldorfastoria hotel in new york city pdf dec   sciclone announces new zadaxinr anticounterfeiting label wins major industry award foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that its newly created anticounterfeiting pharmacomb void label for zadaxin has won the prestigious innovator award in the annual competition sponsored by the tag and label manufacturers institute tlmi the zadaxin label which was pdf nov   sciclone to present at lazard capital markets th annual healthcare conference on november th foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that gary titus chief financial officer will present a corporate overview and business update at the lazard capital markets th annual healthcare conference on november   at  pm et at the pierre hotel in new york city  pdf nov   sciclone reports financial results for the third quarter  and  outlook foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the third quarter and for the nine months ended september   in the third quarter zadaxin® sales continued to perform well with  revenue increase in the quarter and  increase year to date compared pdf nov   sciclone pharmaceuticals to report financial results for the third quarter  and  outlook on november th foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report third quarter  financial results and  outlook on friday november   sciclone will host a conference call and webcast to provide a business and product update at  am et that day the call will be pdf sep   sciclone announces china governmentmandated zadaxinr price reduction anticipates minimal impact on revenue and margins foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that consistent with the china governments review of pharmaceutical prices once a product has been included into the reimbursement drug list rdl the retail list price or hospital pharmacy level price of zadaxin® has been red pdf sep   sciclone announces management transitions in china operations foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that mark lotter will resign from the position of chief executive officer of sciclones china operations at the end of this year and plans to relocate from shanghai to london in order to spend more time with his family at that time mr  pdf aug   sciclone pharmaceuticals to present at investor conferences in september  foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel chief executive officer will present a corporate overview and business update at the biocentury and thomson reuters newsmakers in the biotech industry conference on september   at  am et at the millenni pdf aug   sciclone reports financial results for the second quarter  foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the second quarter and for the six months ended june   results showed strong continued revenue growth on a quarterly and yeartodate basis for zadaxin® the companys flagship product as well as for th pdf aug   sciclone pharmaceuticals to report financial results for the second quarter  on august th foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report second quarter  financial results on wednesday august   sciclone will host a conference call and webcast to provide a business and product update at  pm et that day the call will be hosted by frie pdf may   sciclone pharmaceuticals to present at jefferies global healthcare conference foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that gary titus chief financial officer will present a corporate overview and business update at the jefferies global healthcare conference on june   at  am et at the grand hyatt hotel in new york city to acc pdf may   sciclone increases stock repurchase program foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that its board of directors has approved an increase of approximately  million to the companys stock repurchase program the increase brings the total authorized since the programs inception in october  to approximately  pdf may   sciclone reports financial results for the first quarter  foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the first quarter ended march   revenues increased by  for the quarter ended march   to  million compared to revenues for the same period in the prior year of  million the increases in pdf may   sciclone pharmaceuticals to report financial results for the first quarter  on may th foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report first quarter  financial results on wednesday may   sciclone will host a conference call and webcast to provide a business and product update at  pm et that day the call will be hosted by friedhe pdf apr   sciclone files s registration statement prospectus supplement related to sigmatau transaction foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today filed a prospectus supplement to a previously effective form s registration statement pursuant to which approximately  million shares of sciclone common stock held by certain affiliates of sigmatau were registered for resale under the secu pdf apr   sciclone announces board of directors and officer changes foster city ca  marketwire    sciclone pharmaceuticals inc nasdaq scln today announced the resignation of trevor m jones phd cbe from the board of directors prof jones made this decision based on the increasing demands of his other professional obligations including his involvement in a new business venture and pdf mar   sciclone reports financial results for the fourth quarter and year  and outlook for  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the fourth quarter and year ended december   revenues increased by  for the quarter ended december   to  million compared to revenues for the same period in the prior year of  million pdf mar   sciclone pharmaceuticals to report financial results for the fourth quarter and year ended  and outlook for  on march  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report fourth quarter and full year  financial results on tuesday march   sciclone will host a conference call and webcast to provide a business and product update at  pm et that day the call will be  pdf mar   sciclone announces results of interim analysis of phase  scv oral mucositis trial foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that results from a preplanned interim analysis of the phase b trial of scv in patients with oral mucositis om indicate that the trial would not meet the prespecified efficacy endpoints after conferring with the studys indepe pdf feb   sciclone pharmaceuticals to present at rbc capital markets global healthcare conference foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that gary titus chief financial officer will present a corporate overview and business update at the rbc capital markets global healthcare conference on february   at  noon et at the new york palace hotel in new york cit pdf feb   sciclone pharmaceuticals to present at bio ceo  investor conference foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview and business update at the bio ceo  investor conference  on february   at  am et at the waldorfastoria hotel in ne pdf jan   sciclone provides  financial update and initial  guidance foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced its anticipated fullyear  revenues and yearend cash position and provided its  initial revenue and yearend cash guidance as follows for  the company anticipates revenues of approximately  million u pdf dec   sciclone pharmaceuticals announces final settlement of stockholder derivative litigation foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that the california superior court for the county of san mateo has granted final approval of a settlement reached by the parties to the consolidated derivative lawsuits against certain of its current and former directors and officers of pdf nov   sciclone pharmaceuticals added to the nasdaq biotechnology index foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that the company will be added to the nasdaq biotechnology index® nasdaq nbi the semiannual reranking of the index will become effective prior to market opening on monday november   sciclones inclus pdf nov   sciclone pharmaceuticals to present at three investor conferences in november foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it will present at three upcoming investor conferences sciclones executives will present a corporate overview and business update at each conference cowen and company china opportunity conference tuesday nov pdf nov   sciclone reports financial results for the third quarter of  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the third quarter of  revenues for the quarter were  million compared to  million for the same period last year an increase of  million for the nine months ended september   revenues w pdf nov   sciclone pharmaceuticals to report third quarter  financial results on november  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report third quarter  financial results on tuesday november   sciclone will host a conference call to give a business and product update at  am et that day the call will be hosted by friedhelm blobel  pdf oct   sciclone pharmaceuticals announces preliminary settlement of stockholder derivative litigation foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that the california superior court for the county of san mateo has consolidated the derivative lawsuits pending against certain of its current and former directors and officers and against sciclone pharmaceuticals as a nominal defendan pdf oct   sciclone pharmaceuticals announces share repurchase program and reaffirms  guidance foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that its board of directors has approved a share repurchase program that authorizes the company to repurchase up to  million of its outstanding common stock over the next  months in addition sciclone reaffirmed its previously ann pdf sep   sciclone pharmaceuticals to present at two investor conferences in september foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences rodman  renshaw global investment conference and ubs global life sciences conference sciclones executives will present a corporate overview and business update at each con pdf aug   sciclone reports financial results for the second quarter of  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the second quarter of  revenues for the quarter were  million compared to  million for the same period last year for the six months ended june   revenues were  million compared with  pdf jul   sciclone pharmaceuticals to report second quarter  financial results on august  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report second quarter  financial results on tuesday august   sciclone will host a conference call to give a business and product update at  pm et that day the call will be hosted by friedhelm blobel p pdf jun   sciclone presents new preclinical data highlighting potential role of scv in cancer treatment at  asco annual meeting foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln company today announced new data from preclinical studies of scv the companys lead development product candidate which showed that the compound successfully inhibited the growth of a variety of tumor cell lines in mice these results suggest  pdf jun   sciclone pharmaceuticals to present at the jefferies  global healthcare conference foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview and business update at the jefferies  global healthcare conference on thursday june   at  pm et in new york city  pdf may   sciclone to present new preclinical data on scv at  asco annual meeting foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln company today announced that new data on scv the companys lead development product candidate will be presented at the  american society of clinical oncology asco annual meeting the new data include findings from preclinical studies  pdf may   sciclone pharmaceuticals provides first quarter results and updates  guidance foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the first quarter of  revenues for the quarter grew  to  million compared with the same period last year sciclone reported net income of  million or  per share on a basic and diluted pdf apr   sciclone pharmaceuticals to report first quarter  results on may  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report first quarter  results on tuesday may   sciclone is hosting a conference call at  am et to provide a financial update the call will be hosted by friedhelm blobel phd president and ceo gary pdf apr   sciclone acquires novamed pharmaceuticals further establishing it as a leading chinafocused specialty pharmaceutical company foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln company today announced that it has acquired novamed pharmaceuticals inc novamed a chinabased specialty pharmaceutical company the acquisition brings additional broad sales and marketing as well as regulatory and extensive business capabil pdf mar   sciclone pharmaceuticals provides fourth quarter and year end  results and  guidance foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported results for the fourth quarter and year ended december   revenues for the fourth quarter of  grew to  million or an increase of  compared to revenues of  million in the fourth quarter of  net income for the  pdf mar   sciclone pharmaceuticals to provide financial update on april  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to provide a financial update on friday april   sciclone will host a conference call at  am et on that day the call will be hosted by friedhelm blobel phd president and ceo and gary titus senior vice pre pdf mar   sciclone reports preliminary financial results for the fourth quarter and year end  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported preliminary results for the fourth quarter and year ended december   revenues for the fourth quarter of  grew to  million or an increase of  compared to the fourth quarter of  for the year ended decemb pdf mar   sciclone pharmaceuticals to present at two investor conferences in march foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences cowen healthcare conference and rodman  renshaw annual china investment conference sciclones executives will present a corporate overview and business update at each confere pdf feb   sciclone pharmaceuticals to report fourth quarter and yearend results for  on march  foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report fourth quarter and yearend results for  on wednesday march   sciclone will host a conference call to give a business update and guidance for  at  pm et that day the call will be hosted by  pdf feb   sciclone pharmaceuticals to present at bio ceo  investor conference foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview and business update at the bio ceo  investor conference  on february   at  am et in new york city t pdf jan   sciclone initiates phase b study of scvo for treatment of oral mucositis foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced the enrollment of the first patient in the companys phase b clinical trial of scv for the prevention of oral mucositis om  a painful debilitating and costly toxicity caused by chemoradiotherapy regimens used to treat head and pdf dec   sciclone announces topline results from phase b clinical trial of scv for treatment of chronic hepatitis c foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced topline results from the companys phase b clinical trial of scv for the treatment of hepatitis c hcv the study evaluated the safety and immunomodulatory effects of scv as a monotherapy and in combination with ribavirin in re pdf nov   sciclone pharmaceuticals to present at two investor conferences in november foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences lazard capital markets healthcare conference and piper jaffray health care conference friedhelm blobel phd sciclones president and chief executive officer will present a pdf nov   sciclone reports financial results for the third quarter of  and provides updated guidance for the full year foster city ca  market wire    sciclone pharmaceuticals inc nasdaq scln today reported financial results for the third quarter of  as reported on october   product revenues from sales of zadaxin® were  million an increase of  compared with revenues of  million for the same period last  pdf oct   sciclone announces continued topline growth and strong cash position in the third quarter of  foster city ca oct   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that product sales for the third quarter  rose  over the prior year quarter to reach  million unaudited compared with  million for the same period last year for the nine months ended september  pdf oct   debt financing facility increased to  million foster city ca oct   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that silicon valley bank svb the primary subsidiary of svb financial group nasdaq sivb has increased the existing debt financing facility the bank line to the companys operating subsidiaries the new bank l pdf sep   sciclone identifies unique genetic markers associated with patient response to scv treatment in oral mucositis foster city ca sep   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the companys phase a proof of concept study of scv for the prevention of severe oral mucositis  pdf sep   sciclone pharmaceuticals to present at two investor conferences in september foster city ca sep   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences rodman  renshaw global investment conference and ubs global life sciences conference sciclones executives will present a corporate overview and business up pdf aug   sciclone reports financial results for the second quarter of  and provides updated guidance for the full year foster city ca aug   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the second quarter of  product revenues from sales of zadaxin were  million a decrease of  compared with revenues of  million for the same period last year as previously indicate pdf jul   sciclone pharmaceuticals to present at the bmo capital markets th annual focus on healthcare conference on august  foster city ca jul   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the upcoming bmo capital markets th annual focus on healthcare conference gary titus senior vice president and chief financial officer will present a corporate overview and business update  pdf jul   sciclone pharmaceuticals to report second quarter  financial results and provide a business update on august  foster city ca jul   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report second quarter  financial results on monday august   sciclone will host a conference call to give a business and product update at  pm et that day the call will be hosted by fri pdf jun   sciclone and sigmatau announce final data from clinical trial of zadaxin as hn vaccine enhancer foster city ca jun   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and its partner sigmatau spa announced final results from a clinical study evaluating the potential of zadaxinr thymalfasin to enhance immune response to the mf adjuvanted hn influenza monovalent vaccine focetriar from pdf jun   sciclone pharmaceuticals to present at three investor conferences in june foster city ca jun   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at three upcoming investor conferences jefferies  global life sciences conference needham annual healthcare conference and thinkequity midyear check up on healthcare conference sciclones  pdf may   sciclone provides clinical program update for scv for the prevention of oral mucositis in patients with advanced head and neck cancer foster city ca may   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced further topline results from the companys phase  proof of concept study of scv for the prevention of severe oral mucositis om who grades  in patients with advanced head and neck cancer  a painful and debil pdf may   sciclone pharmaceuticals to present at two investor conferences in may foster city ca may   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences rodman  renshaw annual london investment china conference and the oppenheimer annual china dragon call conference sciclones executives will present a corpo pdf may   sciclone reports financial results for the first quarter of  foster city ca may   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the first quarter of  revenues for the quarter grew  to  million compared with the same period last year sciclone reported net income of  million or  per share compared wit pdf apr   sciclone pharmaceuticals to report first quarter  results on may  foster city ca apr   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report first quarter  results on thursday may   sciclone will host a conference call to give a business and product update at  pm et that day the call will be hosted by friedhelm blobe pdf mar   sciclone announces topline results from phase  clinical trial of scv for prevention of oral mucositis foster city ca mar   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced topline results from the companys phase  clinical trial of scv for the prevention of severe oral mucositis om world health organization who scale grades  to   a painful debilitating and costly toxicity pdf mar   ondansetron rapidfilmtm approved in  european countries foster city ca mar   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the european approval of ondansetron rapidfilmtm codeveloped by apr applied pharma research sa apr and labtec gmbh and licensed to bioalliance pharma sa for european union eu countries bioalliance was pdf mar   sciclone reports financial results for the fourth quarter and year end  and provides commercial and pipeline updates foster city ca mar   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the fourth quarter and year ended december   revenues for the fourth quarter of  grew to  million or  compared to the fourth quarter of  net income for the fourth quarter of  wa pdf mar   sciclone pharmaceuticals to present at three investor conferences in march foster city ca mar   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at three upcoming investor conferences rodman  renshaw annual china investment conference cowen healthcare conference and roth growth stock conference sciclones executives will present a corp pdf feb   sciclone pharmaceuticals to report fourth quarter and yearend results on march   foster city calif feb   business wire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report fourth quarter and yearend results for  on tuesday march   sciclone will host a conference call to give a business and product update and guidance for  at  pm et that pdf feb   sciclone and sigmatau announce additional positive results in clinical study examining zadaxins ability to enhance response to hn vaccine foster city ca and rome feb   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and its partner sigmatau spa announced additional topline results in a clinical study evaluating the potential of zadaxinr thymalfasin to enhance immune response to the mf adjuvanted hn influenza monovalent vacci pdf feb   sciclone pharmaceuticals to present at bio ceo  investor conference foster city ca feb   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview and business update at the bio ceo  investor conference  on february   at  pm et in new york city pdf jan   sciclone and sigmatau announce positive preliminary results in clinical study examining zadaxins ability to enhance response to hn vaccine foster city ca and rome jan   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and its partner sigmatau spa have received initial topline results in a clinical study evaluating the potential of zadaxinr thymalfasin to enhance immune response to the mf adjuvanted hn influenza monovalent vacci pdf jan   sciclone provides  financial update and initial  sales revenue guidance foster city ca jan   marketwire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced its full year  sales revenue  sales revenue guidance and its yearend cash position as follows  for  the company anticipates revenues of approximately  million unaudited a  incre pdf nov   sciclone announces commencement and complete enrollment of clinical study examining zadaxins ability to enhance the hn vaccine led by european partner sigmatau foster city ca nov   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that romebased development partner sigmatau spa has initiated a pilot study in italy to evaluate zadaxins® thymalfasin ability to enhance immune response to the mf adjuvanted hn pdf nov   sciclone announces enrollment completion in phase  oral mucositis trial of scv foster city ca nov   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that patient enrollment is complete ahead of schedule for its phase  trial of scv  a small molecule synthetic peptide with immunomodulating properties  for the treatment of severe oral mucositis om in patients with he pdf nov   sciclone pharmaceuticals to present at the piper jaffray annual healthcare conference foster city ca nov   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the upcoming piper jaffray annual healthcare conference in new york city friedhelm blobel phd sciclones president and chief executive officer will present a corporate overview and business update  pdf nov   sciclone pharmaceuticals announces presentations of scv data at upcoming medical meetings foster city ca nov   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced presentations of multiple abstracts demonstrating scvs antitumor immunomodulating properties at two upcoming events cold spring harbor laboratorys harnessing immunity to prevent and treat disease meeting and the america pdf nov   sciclone reports financial results and provides commercial and pipeline updates for the third quarter of  foster city ca nov   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the third quarter of  revenues for the quarter grew  to  million compared with the same period last year sciclone reported net income of  million or  per share on a basic and diluted  pdf nov   sciclone pharmaceuticals to present at two november investor conferences foster city ca nov   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences in new york city merriman investor summit and lazard capital markets th annual healthcare conference gary titus sciclones senior vice president and chief financial pdf oct   sciclone announces corporate restructuring and workforce reduction foster city ca oct   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced a corporate restructuring that will reduce its usbased workforce by approximately  primarily in research and development this restructuring follows the discontinuation of sciclones rp phase  clinical trial annou pdf oct   sciclone pharmaceuticals to report third quarter  results on november  foster city calif oct   business wire  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report third quarter  results on monday november  sciclone will host a conference call to give a business and product update at  am et that day the call will be hosted by friedhelm blobel phd preside pdf oct   sciclone announces enrollment of first patient in its phase  trial of scv in hepatitis c foster city ca oct   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the enrollment of its first patient at the atlanta gastroenterology associates in atlanta ga in a phase  trial of scv for the treatment of hepatitis c also known as hcv this multicenter multidose openlabel study  pdf oct   phase  trial of rp in latestage pancreatic cancer discontinued foster city ca oct   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the discontinuation of the investigational treatments under its randomized placebocontrolled doubleblind phase  trial that is evaluating rp  a nucleoside analog known as bvdu  for the treatment of latestage pancreat pdf sep   sciclone pharmaceuticals to present at two september investor conferences foster city ca sep   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at two upcoming investor conferences thinkequitys annual growth conference g in san francisco and the ubs global life sciences conference in new york city friedhelm blobel phd sciclones president pdf sep   sciclone pharmaceuticals to present at the rodman  renshaw annual global investment conference foster city ca sep   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the rodman  renshaw annual global investment conference in new york city friedhelm blobel phd sciclones president and chief executive officer will present a corporate overview and business upd pdf aug   sciclone reports financial results and provides pipeline update for the second quarter of  foster city ca aug   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the second quarter of  revenues for the quarter grew  to  million compared with the same period in  sciclone reported net income of  million or  per share on a basic and diluted b pdf jul   sciclone pharmaceuticals to present at the bmo capital markets th annual focus on healthcare conference foster city ca jul   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the bmo capital markets th annual focus on healthcare conference in new york city friedhelm blobel phd sciclones president and chief executive officer will present a corporate overview and busines pdf jul   sciclone pharmaceuticals announces appointment of jon s saxe as chairman of board of directors foster city ca jul   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that dean s woodman current chairman of the board of directors is stepping down from that role while continuing as a board member jon s saxe a sciclone board member of many years will succeed him as chairman dea pdf jul   sciclone pharmaceuticals expands portfolio by licensing ondansetron rapidfilm for chinese market foster city ca and balerna switzerland jul   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln and apr applied pharma research sa apr today announced that they have entered into an exclusive licensing agreement granting sciclone the commercialization rights for aprs innovative antinausea drug ondansetron  pdf jul   sciclone pharmaceuticals to report second quarter  results on august  foster city califbusiness wirejul   sciclone pharmaceuticals inc nasdaqscln today announced that it plans to report second quarter  results on tuesday august   s pdf jun   sciclone pharmaceuticals inc added to russell r index foster city ca jun   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it has been added to the russell ® and russell  indexes the russell  index measures the performance of the largest  us companies and is a combination of the russel pdf may   sciclone pharmaceuticals inc files shelf registration statement foster city ca may   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln has filed a shelf registration statement on form s with the securities and exchange commission sec when the shelf registration statement is declared effective by the sec it will allow sciclone to periodically sell in one or more offe pdf may   sciclone reports financial results for the first quarter of  foster city ca may   marketwire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported financial results for the first quarter of  revenues for the quarter grew  to  million over the same period last year sciclone reported net income of  million or  per share on a basic and diluted basis co pdf apr   sciclone pharmaceuticals to report first quarter  results on may  foster city ca apr   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report first quarter  results on monday may   sciclone will host a conference call to give a business and product update at  pm et that day the call will be hosted by friedhelm blobel phd pdf mar   sciclone and sigma tau reach agreement to resolve director election contest for  annual meeting of sciclone stockholders foster city ca mar   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln sciclone announced today that sciclone and sigmatau finanziaria spa and certain of its affiliated individuals and corporations referred to in this press release collectively as sigmatau have entered into a definitive agreemen pdf mar   sciclone completes enrollment ahead of schedule in phase  trial for rp in latestage pancreatic cancer patients foster city ca mar   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that enrollment has been completed ahead of schedule in the companys phase  clinical trial for rp in patients with latestage pancreatic cancer results from a previous phase  study in  latestage pancreatic cancer  pdf mar   sciclone reports financial results for the fourth quarter and yearend  foster city ca mar   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported results for the fourth quarter and year ended december   the fourth quarter  revenues grew  to  over the same period last year and net loss declined to  or  per share on a basic and  pdf feb   sciclone pharmaceuticals to report fourth quarter and yearend results on march   foster city ca feb   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report fourth quarter and yearend results for  on tuesday march   sciclone will host a conference call to give a business and product update and guidance for  at  am et that day the call pdf feb   sciclone issues guidance breaking through to profitability for the full year of  foster city ca feb   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that revenues for  rose  over the prior year to reach a record  million unaudited sciclone ended  with more than  million in cash the company also issued guidance for continued doubledigit revenue grow pdf feb   sciclone pharmaceuticals to present at bio ceo  investor conference foster city ca feb   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview at the bio ceo  investor conference  on february   at  pm et in new york city dr blobel plans to di pdf jan   sciclone acknowledges receipt of director nomination notice from affiliate of sigmatau foster city ca jan   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln announced today that it has received from defiante farmaceutica sa a company controlled by sigmatau finanziaria spa a notice of intention to nominate four candidates for election to sciclones sevenperson board at the  pdf dec   sciclone announces first patient enrolled in phase  clinical trial using scv to prevent oral mucositis foster city ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the enrollment of its first patient in its phase  multicenter randomized doubleblind placebocontrolled study to assess the safety and efficacy of scv for prevention of oral mucositis om in patients re pdf dec   sciclone pharmaceuticals appoints gary titus as chief financial officer foster city ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the appointment of gary titus as chief financial officer and senior vice president finance effective december   in this position mr titus will use his significant biotechnology industry experience to  pdf nov   sciclone secures six million in debt financing from silicon valley bank foster city ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that silicon valley bank will provide the companys operating subsidiaries a  debt financing the bank line the bank line will be used to provide additional working capital to support sciclones g pdf nov   sciclone reaches agreement with fda on special protocol assessment for phase  thymalfasin trial in stage iv melanoma foster city ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that the company and the us food and drug administration fda have reached agreement on the design of a phase  registration trial for thymalfasin as a potential treatment for stage iv melanoma based on  pdf nov   sciclone reports  percent revenue growth and a profit in the third quarter of  foster city ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the third quarter ended september   among the financial results reported by the biopharmaceutical company revenue from product sales grew  to  over the same period last year an pdf nov   sciclone and sigmatau report phase  hepatitis c trial results foster city ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and sigmatau spa today announced topline results from a large randomized phase  clinical trial evaluating thymalfasin in combination with pegylated interferon alphaa pegifna and ribavirin rbv as a treatment fo pdf oct   sciclone pharmaceuticals to report third quarter  results on november   foster city ca oct   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will report results for the third quarter ended september   and host a conference call on thursday november   management will review operating results for the third quarter  and pdf sep   sciclone provides promising results from its phase a clinical trial using scv as a monotherapy in patients with chronic hepatitis c infection foster city ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced promising results from its proofofconcept phase  clinical trial using its proprietary immunomodulatory compound scv as a sole agent administered to patients chronically infected with the hepatitis c virus  pdf sep   sciclone pharmaceuticals to present at ubs global life sciences conference foster city ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the ubs global life sciences conference at the grand hyatt new york friedhelm blobel phd sciclones president and chief executive officer will present a corporate overview and busines pdf aug   sciclone pharmaceuticals appoints jeffery lange as vice president business development foster city ca aug   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the appointment of jeffery lange as vice president business development effective august   in this position mr lange will leverage his significant biopharmaceutical industry experience to lead business  pdf jul   sciclone reports results for the second quarter of  foster city ca jul   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the second quarter ended june   we achieved outstanding revenue growth in our china business in the second quarter consolidated sales of zadaxin® thymal pdf jul   sciclone pharmaceuticals to report second quarter  results on july   foster city ca jul   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report results for the second quarter ended june   and host a conference call on tuesday july   management will review operating results for the second quarter  and give a b pdf jun   sciclone and sigmatau provide update on phase  hepatitis c study foster city ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and sigmatau spa today announced that all  enrolled patients successfully completed a phase  trial after  weeks of therapy all patients responding to treatment have now completed their week followup the unblinded pdf jun   sciclone pharmaceuticals to hold annual stockholders meeting june   foster city ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will hold its annual meeting of stockholders on tuesday june   at  am pacific time the meeting will be held at the san mateo marriott in san mateo ca registered stockholders are encoura pdf may   sciclone reports results for the first quarter  foster city ca may   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the first quarter ended march   over the course of the first quarter product revenues from zadaxin® sales increased  to exceed  million and for t pdf may   sciclone pharmaceuticals to report first quarter  results on may   foster city ca may   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report first quarter  results and host a conference call on thursday may   management will review operating results for the first quarter  and give a business update the confe pdf apr   sciclone to hold symposium on new therapies in liver cancer and hepatitis c virus foster city ca apr   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced thatit will hold a symposium titled new therapies in liver cancer and hepatitis during the rd annual meeting of the european association for the study of the liver easl in milan italy sciclone and sigmatau pdf nov   sciclone reports third quarter  results foster city ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the third quarter ended september   for the third quarter  product revenues from the sale of zadaxin® thymalfasin sciclones lead product increased pdf nov   sciclone to present at bioeurope  conference on november   foster city ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview at bioeurope  an international partnering conference the presentation is scheduled for november   pdf oct   sciclone pharmaceuticals to report third quarter  results on november   foster city ca oct   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report third quarter  results and host a conference call on tuesday november   the conference call will contain forwardlooking statements financial and statistical information t pdf sep   sciclone pharmaceuticals to present at ubs global life sciences conference san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the ubs global life sciences conference at the grand hyatt new york friedhelm blobel phd sciclones president and chief executive officer will present a corporate overview and business pdf aug   sciclone reports second quarter  results san mateo ca aug   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the second quarter ended june   for the second quarter  product revenues from the sale of zadaxin® thymalfasin sciclones lead product increased by  pdf jul   sciclone pharmaceuticals to report second quarter  results on august   san mateo ca jul   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report second quarter  results and host a conference call on tuesday august   the conference call will contain forwardlooking statements financial and statistical information to be  pdf jun   sciclone initiates phase  clinical trial using scv to treat hepatitis c patients san mateo ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced it has initiated a proofofconcept phase  clinical trial using its proprietary compound scv as a sole agent to treat patients infected with the hepatitis c virus hcv the trial is designed to evaluate the th pdf jun   sciclones scv inhibits melanoma tumor growth in animal model study san mateo ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported data showing that scv inhibits the growth of melanoma tumors in an animal model study these data were the subject of an abstract accepted for the annual meeting of the american society of clinical oncology in ch pdf jun   sciclone and sigmatau report thymalfasin meets primary endpoint in phase  malignant melanoma trial san mateo ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and sigmatau spa today announced that sciclones lead product candidate thymalfasin zadaxin® thymosin alpha  achieved its primary endpoint in a phase  clinical trial treating patients di pdf may   sciclone reports first quarter  results san mateo ca may   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the first quarter ended march   over the course of the first quarter we continued to increase our sales of zadaxin® in china and are in the process of ex pdf may   sciclone pharmaceuticals to report first quarter results on may   san mateo ca may   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report first quarter  results and host a conference call on tuesday may   the conference call will contain forwardlooking statements financial and statistical information to be dis pdf apr   sciclone announces zadaxin and scv abstracts accepted at asco san mateo ca apr   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that the following abstracts have been accepted for the annual meeting of the american society of clinical oncology in chicago illinois on june   zadaxin® thymalfa pdf apr   sciclone acquires clinicalstage pancreatic cancer compound san mateo ca apr   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it has acquired the exclusive rights in the united states and canada to develop and commercialize rp a clinicalstage compound for the treatment of cancer sciclone acquired the rights from resistys inc pdf mar   sciclone reports fourth quarter and year end  results an mateo ca mar   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the fourth quarter and full year ended december   we achieved several substantial clinical financial and regulatory milestones over the course of the last twelve months we reported positive  pdf mar   sciclone pharmaceuticals to report fourth quarter and year end results on march   san mateo ca mar   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report fourth quarter and year end  results and host a conference call on thursday march   the conference call will contain forwardlooking statements financial and statistical inf pdf feb   sciclone pharmaceuticals to present at bio ceo and investor conference on february   san mateo ca feb   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview at the bio ceo and investor conference  on february   at  am et in new york new york to ac pdf feb   sciclone announces accelerated clinical development plans for scv san mateo ca feb   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that based on an extensive review of positive human clinical trial and animal model results it will initiate a controlled phase  doseranging clinical trial using its proprietary compound scv in the second quar pdf dec   sciclone and sigmatau complete enrollment in phase  triple therapy hepatitis c clinical trial san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and its european partner sigmatau spa today announced that full patient enrollment is complete for its phase  clinical trial evaluating the use of zadaxin® thymalfasin or thymosin alpha  pdf dec   sciclone submits regulatory application for dc bead in china san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it has submitted a regulatory application to the chinese state food and drug administration sfda for approval to market the dc bead a product for the treatment of liver pdf dec   sciclone pharmaceuticals adopts stockholders rights plan san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln announced today that its board of directors has adopted a stock purchase rights plan designed to enable all sciclone stockholders to realize the full value of their investment and to provide for fair and equal treatment for all sci pdf dec   sciclone and sigmatau announce positive interim survival data from large phase  malignant melanoma trial san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and sigmatau spa today announced positive interim survival data from a large phase  trial treating patients with stage iv malignant melanoma the most advanced form of this cancer data from the first four arms of this ongoing pdf nov   alfred rudolph md is leaving as chief operating officer san mateo ca nov   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced that alfred rudolph md chief operating officer is leaving the company effective november   the company is actively working to identify a successor in the interim friedhelm blobel phd president and pdf nov   sciclone pharmaceuticals to present at the bioeurope th annual international partnering conference san mateo ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the bioeurope th annual international partnering conference at the congress center sued stadthalle in duesseldorf germany on november   at  am cet friedhelm blobel phd pdf oct   sciclone reports third quarter  results san mateo ca oct   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the third quarter ended september   for the third quarter  revenues from the sale of zadaxin® sciclones lead product increased by  to  pdf oct   sciclone pharmaceuticals to present at the rodman  renshaw healthcare conference san mateo ca oct   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the rodman  renshaw healthcare conference on monday november   at  pm est to access the live audio webcast of the presentation log on through a link located in  pdf oct   sciclone pharmaceuticals to report third quarter  results on october   an mateo ca oct   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report third quarter  results and host a conference call on tuesday october   the conference call will contain forwardlooking statements financial and statistical information  pdf oct   sciclone pharmaceuticals to webcast presentation at bio investorforum conference san mateo ca oct   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that friedhelm blobel phd president and chief executive officer will present a corporate overview at the bio investorforum  conference on wednesday october   at  pm pdt in san francisco ca pdf sep   sciclones new ceo unveils focused global strategic vision san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln announced that friedhelm blobel phd sciclones recently appointed president and chief executive officer will unveil a focused global strategic vision and upcoming milestones during his presentation at the ubs global life sc pdf sep   sciclone and sigmatau present encouraging interim phase  metastatic malignant melanoma response data san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and sigmatau spa today reported interim data showing that the addition of zadaxin® to standard dacarbazine dtic chemotherapy with or without interferon alpha in patients with stage iv pdf sep   sciclone pharmaceuticals to present at ubs global life sciences conference san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it will present at the ubs global life sciences conference at the grand hyatt new york friedhelm blobel phd sciclones president and chief executive officer will deliver a corporate overview presentat pdf sep   sciclones scv demonstrates oral bioavailability san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported phase  data indicating that scv taken orally was safe and led to circulating plasma concentrations similar to those obtained in previous phase  studies using a subcutaneous injection of scv importantly s pdf aug   sciclone reports second quarter  results san mateo ca aug   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the second quarter ended june   for the second quarter  revenues from the sale of zadaxin® sciclones lead product increased by  to  c pdf jul   sciclone to report second quarter  results on august   san mateo ca jul   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report second quarter  results and host a conference call on tuesday august   the conference call will contain forwardlooking statements financial and statistical informati pdf jun   sciclone acquires exclusive rights in china to dc bead chemoembolization device san mateo ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it has entered into a three year agreement with biocompatibles international plc lse bii granting sciclone exclusive rights to market biocompatibles dc beadtm chemotherapy releasing device within china pdf jun   sciclone announces presentation of preclinical data showing oral scv efficacy against tuberculosis san mateo ca jun   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the presentation of preclinical data demonstrating that scv in an oral formulation retains its immunomodulatory properties and is as effective as the standard injection formulation against tuberculosis tb i pdf may   sciclone reports final results from second zadaxin us phase  hepatitis c trial san mateo ca may   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported final results from its second us phase  hepatitis c virus hcv trial evaluating the benefit of adding zadaxin® to pegylated interferon alpha treatment for hcv patients with pdf may   sciclone reports first quarter  results san mateo ca may   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the first quarter ended march   for the first quarter  revenues from the sale of zadaxin® sciclones lead product increased by  to  co pdf apr   sciclone pharmaceuticals announces appointment of new ceo san mateo ca apr   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the appointment of dr friedhelm blobel as president chief executive officer and a director of the company effective as of june   ira lawrence md will continue as president and ceo until june    pdf apr   sciclone announces presentation of preclinical data showing scv enhances protective effect of tuberculosis vaccine san mateo ca apr   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the presentation of data from a preclinical study demonstrating that the administration of scv in conjunction with the bcg tuberculosis tb vaccine resulted in a significantly superior protective effect agai pdf apr   sciclone announces settlement of schering plough kk spkk dispute san mateo ca apr   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it has reached a settlement in its dispute with spkk concerning clinical trials conducted in japan with zadaxin® sciclones lead compound under this resolution sciclo pdf mar   sciclone announces presentation of zadaxin phase  liver cancer data at shanghaihong kong international liver congress san mateo ca mar   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced the presentation of data from its phase  hepatocellular carcinoma or primary liver cancer trial at the shanghaihong kong international liver congress dr robert gish md medical director liver transplan pdf mar   sciclones zadaxin granted orphan drug designation for malignant melanoma in united states san mateo ca mar   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that thymalfasin the chemical composition of zadaxin® has been granted orphan drug designation for the treatment of stage iib through stage iv malignant melanoma by the us pdf mar   sciclone reports results for fourth quarter and yearend  san mateo ca mar   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the fourth quarter and full year ended december   for the fourth quarter  revenues from the sale of zadaxin® sciclones lead product increased by  pdf feb   sciclone to report fourth quarter and yearend  results on march   san mateo ca feb   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced that it plans to report fourth quarter and yearend  results and host a conference call on wednesday march   the conference call will contain forwardlooking statements financial and statist pdf dec   sciclone reports results from zadaxin proofofconcept liver cancer trial san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today reported data from its small phase  proofofconcept hepatocellular carcinoma liver cancer trial indicating a trend toward positive survival benefit in patients treated with zadaxin® plus tra pdf dec   sciclone reports results from first zadaxin phase  hepatitis c trial san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today announced topline results from the first of its two phase  clinical trials using zadaxin® thymalfasin in combination with pegylated interferon alpha to treat patients with hepatitis pdf dec   sciclone and sigmatau report promising interim phase  results in advancedstage malignant melanoma trial san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln and sigmatau spa today announced promising interim results from a large phase  clinical trial evaluating zadaxin® thymalfasin in combination with dacarbazine dtic chemotherapy with an pdf dec   sciclone to host a conference call december   to discuss zadaxin phase  hepatitis c results and interim phase  malignant melanoma data san mateo ca dec   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced that it will report zadaxin® phase  hepatitis c results and interim phase  malignant melanoma data before the market opens on wednesday december   and host a conference ca pdf nov   sciclone announces data presentations at aasld regarding zadaxins activity in hepatitis b san mateo ca nov   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced abstract presentations of preclinical and clinical data from two separate studies evaluating the activity of zadaxin® also known as thymosin alpha  against the hepatitis b virus pdf nov   sciclone to present at rodman and renshaw techvest healthcare conference san mateo ca nov   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced that it will present at the rodman and renshaw techvest healthcare conference at the new york palace hotel in new york ira d lawrence md sciclones president and chief executive officer will deliver a corporate pdf nov   sciclone reports third quarter  results san mateo ca nov   market wire via comtex news network  sciclone pharmaceuticals inc nasdaq scln today reported results for the third quarter and nine months ended september   for the third quarter  revenues from the sale of zadaxin® sciclones lead product were  pdf oct   sciclone pharmaceuticals to present at biotechnology industry organization bio investor forum san mateo ca oct   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced that it will present at the bio investor forum conference at the palace hotel in san francisco ira d lawrence md sciclones president and chief executive officer will deliver a corporate overview presentation o pdf oct   sciclone to report third quarter  results on november   san mateo califbusiness wireoct  sciclone pharmaceuticals inc nasdaqscln today announced that it plans to report third quarter  results and host a conference call on tuesday november   the conference call will contain forwardlooking statements financial and statistical information to be discussed pdf oct   sciclone names israel rios md as chief medical officer san mateo ca oct   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced the appointment of israel rios md as chief medical officer dr rios brings to sciclone over  years of pharmaceutical industry knowledge and extensive experience in clinical development and the regulatory approval pdf sep   sciclone to report topline data from first us hepatitis c phase  trial by middecember  san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced that it expects to unblind and report topline data by middecember  from the first of its two us phase  hepatitis c virus hcv clinical trials evaluating its lead compound zadaxin® pdf sep   sciclone pharmaceuticals to present at ubs global life sciences conference san mateo ca sep   market wire via comtex news network  sciclone pharmaceuticals nasdaq scln today announced that it will present at the ubs global life sciences conference at the grand hyatt new york ira d lawrence md sciclones president and chief executive officer will deliver a corporate overview presentation on t pdf aug   sciclone reports second quarter  results san mateo ca aug   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported results for the second quarter and six months ended june   for the second quarter  revenues from the sale of zadaxin® sciclones lead product reached  an increase pdf jul   sciclone presents preclinical data demonstrating scvs activity in human papillomavirus and lassa fever models san mateo ca jul   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that its proprietary immunomodulatory compound scv was effective in preclinical studies significantly reducing lesions in a model of human papillomavirus hpv and increasing survival in a model of lassa fever  pdf jul   sciclone to report second quarter  results on august   san mateo califbusiness wirejuly  sciclone pharmaceuticals inc nasdaqscln today announced that it plans to report second quarter  results and host a conference call on august   the conference call will contain forwardlooking statements financial and statistical information to be discussed on the ca pdf jun   sciclone files ind application for scv san mateo ca jun   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the submission of an investigational new drug ind application to the us food and drug administration fda for scv a synthetic dipeptide that has demonstrated activity against a broad range of viral and infectious dis pdf jun   sciclone announces zadaxin hepatitis c triple therapy poster presentation san mateo ca jun   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the poster presentation of additional data evaluating its lead product candidate zadaxin® thymosin alpha  in combination with pegylated interferon alpha and ribavirin as a potential t pdf jun   sciclone comments on recent trading activity san mateo ca jun   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today commented that the current market activity in its stock could be the result of an article reporting that sonae sgps sa a portuguese company is preparing to make a tender offer for sciclone sciclone had not been contacted by sonae  pdf may   sciclone reports first quarter  results san mateo ca may   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported results for the first quarter ended march   for the first quarter  revenues from the sale of zadaxin® sciclones lead product reached  an increase of approximatel pdf apr   sciclone names ira d lawrence md to serve as president and chief executive officer san mateo ca apr   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the appointment of ira d lawrence md as president chief executive officer and a member of the board of directors effective june   dr lawrence brings extensive international pharmaceutical company management and pdf apr   sciclone to report first quarter  results on may   san mateo califbusiness wireapril  sciclone pharmaceuticals inc nasdaqscln today announced that it plans to report first quarter  results and host a conference call on may   the conference call will contain forwardlooking statements financial and statistical information to be discussed on the call w pdf apr   sciclone announces presentation of zadaxin mechanism of action at american association of immunologists conference san mateo ca apr   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the presentation of results from a laboratory study that provides further insight into the mechanism of action of zadaxin® sciclones lead product candidate specifically this study rev pdf feb   sciclone reports results for fourth quarter and full year  san mateo ca feb   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today reported results for the fourth quarter and full year ended december   for the fourth quarter  revenues from the sale of zadaxin sciclones lead product increased  to  compared to  for the fourt pdf feb   sciclone reports management change san mateo ca feb   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that eduardo b martins md dphil vice president of medical affairs has resigned in order to accept a position with another biopharmaceutical company on behalf of our entire company i would like to thank ed pdf feb   sciclone announces the appointment of dean s woodman to chairman of the board of directors san mateo ca feb   market wire via comtex  sciclone pharmaceuticals inc nasdaq scln today announced the appointment of dean s woodman to chairman of the board of directors dr jere e goyan will continue as chairman emeritus mr woodman has served as a director on sciclones board of directors since august  in a pdf jan   sciclone to report fourth quarter  results on february   san mateo califbusiness wirejan  sciclone pharmaceuticals inc nasdaqscln today announced that it plans to report fourth quarter and full year  results and host a conference call on february   the conference call will contain forwardlooking statements financial and statistical information to be di pdf dec   sciclones zadaxin added to asian pacific consensus recommendation for treatment of hepatitis b san mateo califbusiness wiredec  sciclone pharmaceuticals inc nasdaqscln today announced that its lead product zadaxin® was added to the asian pacific consensus recommendation for the treatment of patients infected with the hepatitis b virus hbv the asian pacific consensus recommen pdf dec   sciclones european partner sigmatau initiates phase  zadaxin hepatitis c triple therapy trial first patients enrolled and receiving treatment san mateo califbusiness wiredec  sciclone pharmaceuticals inc nasdaqscln today announced that sigmatau its european development and marketing partner for zadaxin® has begun enrolling patients infected with the hepatitis c virus hcv in a multicenter european phase  clinical tria pdf nov   sciclone reports third quarter results san mateo califbusiness wirenov  sciclone pharmaceuticals inc nasdaqscln today reported results for the third quarter and nine months ended september   revenues from sales of zadaxin® sciclones lead product candidate were  for the third quarter and  for  pdf nov   sciclone announces appointment of richard j hawkins to board of directors san mateo califbusiness wirenov  sciclone pharmaceuticals inc nasdaqscln today announced the appointment of richard j hawkins to the companys board of directors as a nonexecutive member ricks experience in drug development regulatory approval and the leadership of rapidly growing pharmaceutical companies pdf nov   sciclones zadaxin shows promise in triple therapy trial for hepatitis c nonresponder patients endpoint data presented at worlds largest meeting of liver specialists san mateo califbusiness wirenov  sciclone pharmaceuticals inc nasdaqscln today reported that triple therapy of zadaxin® combined with pegylated interferon and ribavirin in a pilot trial in mexico showed a sustained virologic response svr in  of difficult to treat hepatitis c patie pdf oct   sciclone to report third quarter  results on november   san mateo califbusiness wireoct  sciclone pharmaceuticals nasdaqscln today announced that it expects to report third quarter  financial results on monday november   before the market opens and host a conference call and live audio webcast at  am est that day the conference call will include forwardlookin pdf oct   sciclone announces zadaxin poster to be presented at aasld san mateo califbusiness wireoct  sciclone pharmaceuticals inc nasdaqscln today announced the following poster presentation on zadaxin® thymosin alpha  thymalfasin at the american association for the study of liver diseases aasld meeting in boston a pilot trial of thy pdf sep   sciclone pharmaceuticals to present at ubs global life sciences conference san mateo califbusiness wiresept  sciclone pharmaceuticals nasdaqscln today announced that it will present at the ubs global life sciences conference at the grand hyatt in new york richard a waldron sciclones chief financial officer will deliver a corporate overview presentation on wednesday september   at  pdf aug   sciclones collaborative partner awarded us government grant to evaluate scv san mateo califbusiness wireaug  sciclone pharmaceuticals inc nasdaqscln today announced that its collaborative partner verta ltd has been awarded a grant from the us government to evaluate the therapeutic potential of scv in a hepatitis c virus hcv proofofconcept trial in russia based on earlier studies sh pdf aug   sciclone reports second quarter results san mateo califbusiness wireaug  sciclone pharmaceuticals inc nasdaqscln today reported results for the second quarter and six months ended june   revenues from sales of zadaxin® sciclones lead product candidate were  for the second quarter and  for the  pdf jul   sciclone to report second quarter  results on august   san mateo califbusiness wirejuly  sciclone pharmaceuticals nasdaqscln today announced that it expects to report second quarter  financial results on wednesday august   before the market opens and host a conference call and live audio webcast at  am edt that day the conference call will include forwardloo pdf jul   donald r sellers resigns as president and ceo of sciclone san mateo califbusiness wirejuly  sciclone pharmaceuticals inc nasdaqscln today announced that don sellers has resigned as president and ceo of the company after  years of service mr sellers also has resigned from the board of directors however he will continue to act as a consultant to the company the board of dir pdf jun   sciclones zadaxin shows promising effects in treating brain cancer in animal model study san mateo califbusiness wirejune  sciclone pharmaceuticals inc nasdaqscln today announced the results of an animal model study evaluating its lead candidate zadaxin® in combination with carmustine bcnu a chemotherapy agent commonly used to treat brain tumors as a potential therapy  pdf may   sciclone announces collaboration to develop pegylated zadaxin san mateo califbusiness wiremay  sciclone pharmaceuticals inc nasdaqscln today announced that it has entered into a collaborative agreement with nektar therapeutics nasdaqnktr subsidiary nektar therapeutics al corporation to develop a pegylated formulation of zadaxin® nektar wil pdf may   sciclone phase  zadaxin triple therapy hepatitis c trial in europe san mateo califbusiness wiremay  sciclone pharmaceuticals inc nasdaqscln today announced a multicenter phase  hepatitis c triple therapy clinical trial in europe sciclones european marketing and development partner sigmatau will conduct this phase  multicenter double blinded study in approximately  patients wi pdf may   sciclone achieves enrollment milestone for us phase  hepatitis c trials earns  milestone payment san mateo calif may   business wire  sciclone pharmaceuticals inc nasdaqscln today announced that a total of  patients have been enrolled in its two us phase  hepatitis c hcv clinical trials evaluating its lead product zadaxin® sciclone has earned a  milestone paym pdf may   sciclone pharmaceuticals to present at ubs global specialty pharmaceuticals conference san mateo califbusiness wiremay  sciclone pharmaceuticals nasdaqscln today announced that it will present at the ubs global specialty pharmaceuticals conference on monday may   at  am edt donald r sellers sciclones president and chief executive officer will deliver a corporate overview presentation follow pdf apr   sciclone reports first quarter results san mateo califbusiness wireapril  sciclone pharmaceuticals inc nasdaqscln today reported results for the first quarter ended march   revenues from sales of zadaxin® the companys lead product totaled  an  increase over the  reported for the first quarte pdf apr   sciclone explores new combination therapy in hepatitis b clinical trial trial uses high dose of zadaxin in combination with lamivudine san mateo califbusiness wireapril  sciclone pharmaceuticals nasdaqscln today announced an ongoing randomized placebocontrolled clinical trial in taiwan using a high dose of zadaxin® in combination with lamivudine the most widely used treatment for chronic hepatitis b to explore the po pdf apr   sciclone to report first quarter  results on april   san mateo califbusiness wireapril  sciclone pharmaceuticals nasdaq scln today announced that it expects to report first quarter  financial results on tuesday april   before the market opens and host a conference call and live audio webcast at  pm edt that day the conference call will include forwardlooki pdf mar   sciclones zadaxin demonstrates significant antifungal efficacy in invasive aspergillosis animal study san mateo califbusiness wiremarch  sciclone pharmaceuticals nasdaqscln today announced the publication of results from a new animal model study demonstrating for the first time that its lead drug candidate zadaxin® is an effective antifungal treatment for invasive aspergillosis the st pdf feb   sciclone reports results for fourth quarter and full year  san mateo califbusiness wirefeb  sciclone pharmaceuticals inc nasdaqscln today reported results for the fourth quarter and full year ended december   revenues from sales of zadaxin® the companys lead immune system enhancer drug were  for the fourth quarter of  pdf feb   sciclone reports data  of hepatitis c nonresponder patients test hcv rna negative after  weeks of zadaxin triple therapy san mateo califbusiness wirefeb  sciclone pharmaceuticals inc nasdaqscln  pilot trial treating patients not responding to prior therapy continues to show positive results sciclone pharmaceuticals inc nasdaqscln today reported positive data from a pilot clinical trial in hepati pdf feb   sciclone to report fourth quarter  results on february   san mateo califbusiness wirefeb  sciclone pharmaceuticals nasdaqscln today announced that it expects to report fourth quarter  results on tuesday february   before the market opens and host a conference call and live audio webcast at  pm est that day the conference call will include forwardlooking state pdf dec   sciclone pharmaceuticals to present at harris nesbitt gerard healthcare conference san mateo califbusiness wiredec  sciclone pharmaceuticals nasdaq scln today announced that it will present at the harris nesbitt gerard healthcare conference on thursday december   at  am est donald r sellers sciclones president and chief executive officer will deliver a corporate overview presentation the pr pdf oct   sciclones zadaxin in triple therapy shows  early virologic response for hepatitis c nonresponders week data presented at worlds largest meeting of liver specialists san mateo califbusiness wireoct  sciclone pharmaceuticals inc nasdaq scln today reported positive data from a triple therapy pilot study showing zadaxin® in combination with pegylated interferon alpha and ribavirin produced a week early virologic response evr in  of hepatitis  pdf oct   sciclone reports third quarter results sales of zadaxin increase  to  million san mateo califbusiness wireoct  sciclone pharmaceuticals inc nasdaqscln today reported results for the third quarter ended september   revenues from sales of zadaxin® the companys lead immune system enhancer drug were  for the third quarter of  a  increas pdf oct   sciclone to report third quarter  results on october   san mateo califbusiness wireoct  sciclone pharmaceuticals nasdaqscln today announced that it expects to report third quarter  results on monday october   before the market opens and host a conference call and live audio webcast at  pm est  am pst on the same day the conference call will include  pdf oct   sciclone receives us government grant to develop oral formulation of scv grant also funds additional phase  tuberculosis clinical trials in russia san mateo califbusiness wireoct  sciclone pharmaceuticals nasdaqscln today announced that it has received a grant from the us government to develop an oral formulation for scv sciclones proprietary compound that enhances the immune system in previous phase  clinical trials scv formulated as an injectable produc pdf oct   sciclone announces zadaxin poster to be presented at aasld san mateo califbusiness wireoct  sciclone pharmaceuticals inc nasdaqscln today announced the following poster presentation on zadaxin® thymosin alpha  thymalfasin at the american association for the study of liver diseases aasld meeting in boston a pilot trial of thy pdf sep   sciclone completes enrollment of  patients in first of two phase  hepatitis c trials san mateo califbusiness wiresept  sciclone pharmaceuticals inc nasdaqscln announced today that it has completed the planned enrollment of  patients in the first of its two phase  hepatitis c hcv clinical trials evaluating its lead immune system enhancing drug zadaxin sciclone intends to complete enrollment of the  pdf sep   sciclone announces offering of  shares of common stock san mateo calif sep   business wire  sciclone pharmaceuticals inc nasdaqscln announced that it commenced today the public offering of  shares of its common stock all shares are being offered by sciclone in addition the underwriters have a day period in which to exercise an option to purchase up to  a pdf jul   sciclone announces filing of registration statement for public offering of common stock san mateo califbusiness wirejuly  sciclone pharmaceuticals inc the company nasdaqscln announced today that it has filed a registration statement with the securities and exchange commission for the public offering of  shares of its common stock all shares will be offered by the company in addition the underwr pdf jul   sciclone reports second quarter results record zadaxin sales of  million and net income of  million san mateo calif jul   business wire  sciclone pharmaceuticals inc nasdaqscln today reported net income of  or  per fully diluted share for the second quarter ended june   revenues from sales of zadaxin® the companys lead immune system enhancer drug reached a pdf jul   sciclone announces completion of reincorporation and termination of rights agreement san mateo califbusiness wirejuly  sciclone pharmaceuticals inc nasdaqscln today announced that it has completed its previously announced reincorporation from the state of california to the state of delaware in connection with the reincorporation sciclone terminated its shareholder rights agreement as previou pdf jul   sciclone to report second quarter  results on july   san mateo califbusiness wirejuly  sciclone pharmaceuticals nasdaqscln today announced that it expects to report second quarter  results on monday july   before the market opens and host a conference call and live audio webcast at  pm edt  am pdt on the same day the conference call will include forwar pdf jul   sciclone sponsors zadaxin symposium at international conference for the study of the liver panel of experts discuss zadaxin as a treatment for hepatitis c and b san mateo califbusiness wirejuly  sciclone pharmaceuticals inc nasdaqscln announced that it is sponsoring a satellite symposium today at the european association for the study of the liver easl in geneva switzerland at the symposium internationally renowned experts in immunology and liver disease plan to discuss zadax pdf jun   sciclones shareholders approve reincorporation in delaware san mateo califbusiness wirejune  sciclone pharmaceuticals inc nasdaqscln today announced that shareholders voted in favor of the  proxy proposals to reincorporate in the state of delaware and each of the additional charter revisions shareholders also voted to reelect all seven directors to approve ernst  young pdf jun   sciclone announces positive data from phase  hepatitis b trial in japan begins japanese new drug application process san mateo califbusiness wirejune  sciclone pharmaceuticals inc nasdaqscln at its annual meeting of shareholders today announced positive data from its phase  clinical trial in japan using its lead immune system enhancing drug zadaxin as a treatment for hepatitis b efficacy measurements showed that  of patients had ne pdf jun   study demonstrates mechanism of action for sciclones scv in treating tuberculosis san mateo califbusiness wirejune  sciclone pharmaceuticals nasdaqscln today announced the results of a tuberculosis tb animal model study demonstrating the mechanism of action of scv the companys proprietary compound that enhances the immune system the study showed that scv stimulated a th immune response which pdf jun   sciclone selected for russell  index san mateo califbusiness wirejune  sciclone pharmaceuticals inc nasdaqscln today announced that it has been selected to be added to the russell ® index as part of russells annual reconstitution of its equity indexes additions will take place on tuesday july   and will rema pdf may   sciclones largest shareholders support proxy proposals san mateo califbusiness wiremay  sciclone pharmaceuticals today announced that its two largest shareholders sigmatau and randal j kirk have advised sciclone that they intend to vote in favor of the proposed reincorporation in the state of delaware and certain additional charter revisions to be considered at the june   pdf may   sciclone pharmaceuticals to present at ubs warburgs global specialty pharmaceuticals conference san mateo califbusiness wiremay  sciclone pharmaceuticals nasdaqscln today announced that it will present at ubs warburgs global specialty pharmaceuticals conference on thursday june   at  pm edt donald r sellers sciclones president and chief executive officer will deliver a corporate overview presentation  pdf may   cboe to list options on sciclone common stock san mateo calif may   business wire  sciclone pharmaceuticals nasdaqscln today announced that the chicago board options exchange cboe will list options under the ticker symbol suv on sciclone common stock beginning thursday may   for more information on new listings visit the trading tools section of the cboe we pdf may   sciclone added to nasdaq biotech index san mateo califbusiness wiremay  sciclone pharmaceuticals inc nasdaqscln today announced that it has been selected to be added to the nasdaq biotechnology index nbi effective monday may   all securities in the index are listed on the nasdaq national market and meet minimum requirements including market value a pdf may   sars related zadaxin sales to china expected to increase second quarter revenue to over  million san mateo califbusiness wiremay  sciclone pharmaceuticals inc nasdaqscln today announced that sars related export sales to china are expected to drive sales of zadaxin® the companys lead immune system enhancing drug to more than  million for the second quarter of  this compar pdf apr   sciclone reports first quarter results record zadaxin sales for first quarter  san mateo califbusiness wireapril  sciclone pharmaceuticals inc nasdaqscln today reported results for the first quarter ended march   revenues from sales of zadaxin® the companys lead immune system enhancer drug reached a record  a  increase over the  pdf apr   sciclone to report first quarter  results on april   san mateo calif apr   business wire  sciclone pharmaceuticals nasdaqscln today announced that it expects to report first quarter  results on thursday april   before the market opens and host a conference call and live audio webcast at  pm est  am pst on the same day the conference call will include f pdf apr   zadaxin combination therapy shows  sustained response in hepatitis b patients san mateo calif apr   business wire  sciclone pharmaceuticals nasdaqscln today announced the results of a study showing a  longterm sustained response rate for difficult to treat hepatitis b patients these results were achieved after only one year of combination therapy with zadaxin and interferon alpha this sustained  pdf feb   sciclone pharmaceuticals to present at redchip investor conference in boston san mateo calif feb   business wire  sciclone pharmaceuticals inc nasdaqscln a biopharmaceutical company engaged in the development of therapeutics to treat lifethreatening diseases announced that it will present at redchip partners investor conference in boston on wednesday february   at  am eastern standard  pdf feb   sciclone reports record zadaxin sales for fourth quarter and full year  phase  hepatitis b clinical trial in japan completed on schedule san mateo calif feb   business wire  sciclone pharmaceuticals inc nasdaqscln today reported results for the fourth quarter ended december   revenues from sales of zadaxin® the companys lead immune system enhancer drug reached a record  a  increase over the  pdf jan   sigmatau increases equity position in sciclone sigmatau group invests additional  million in sciclone san mateo califbusiness wirejan  sciclone pharmaceuticals inc nasdaqscln today announced that sigmatau and its affiliates increased their aggregate ownership to close to  of sciclones common stock outstanding by purchasing approximately  unregistered shares of common stock directly from the company for  m pdf jan   sciclone to report  results february   japanese phase  hepatitis b trial completed on schedule san mateo califbusiness wirejan  sciclone pharmaceuticals nasdaqscln today announced that it expects to report fourth quarter and fiscal year  results on tuesday feb   before the market opens and host a conference call and live audio webcast at  pm est  am pst on the same day the conference call pdf dec   sciclone pharmaceuticals to present at ccbns virtual healthcare conference san mateo califbusiness wiredec  sciclone pharmaceuticals inc nasdaq scln will present at ccbns virtual healthcare conference on tuesday december   at  pm est  pm pst donald r sellers sciclones president and chief executive officer will deliver a corporate overview presentation which will be webcast li pdf nov   sciclone pharmaceuticals to present at redchip investor conference in phoenix biowirek san mateo califbusiness wirenov  sciclone pharmaceuticals inc nasdaqscln a biopharmaceutical company primarily focused on the development of immune system enhancers ises for the treatment of infectious diseases and cancer announced that it will present at redchip partners investor conference in phoenix on satu pdf nov   zadaxin significantly increases survival in melanoma animal study study presented at american society of clinical oncologists asco meeting biowirek san mateo califbusiness wirenov  sciclone pharmaceuticals inc nasdaqscln today reported results from a new animal model study demonstrating that zadaxin treatment following standard chemotherapy for melanoma significantly increases survival in the study  of the group treated with zadaxin via continu pdf nov   sciclone pharmaceuticals reports third quarter  results new data support clinical trials zadaxin sales up  san mateo calif nov   business wire  sciclone pharmaceuticals inc nasdaqscln today reported results from the third quarter ended september   revenues from sales of zadaxin the companys lead immune system enhancer drug were  a  increase over the  reported during the third quarter of  in a pdf nov   zadaxin adds benefit to pegylated interferon for hcv nonresponders hepatitis c patients who failed prior therapy responding to zadaxin san mateo calif nov   business wire  zadaxin® in combination with pegylated interferon advanced in its effort to be part of the first approved hepatitis c therapy for nonresponders close to half of all patients fail to respond to initial treatment with currently available therapies and become non pdf oct   zadaxin shows direct antiviral effects on cells infected with hepatitis b and hiv san mateo calif oct   business wire  sciclone pharmaceuticals inc nasdaqscln today reported that zadaxin® in addition to previously observed immunological effects for the first time has shown direct antiviral effects on cells infected with the hepatitis b virus hbv and human immunodeficie pdf oct   sciclone pharmaceuticals to release third quarter  results on november   conference call and webcast scheduled san mateo calif oct   business wire  sciclone pharmaceuticals nasdaqscln announced that its third quarter  results will be released on monday november   before the market opens a conference call and live webcast have been scheduled for  pm est  am pst donald sellers president and chief executive officer ri pdf sep   sciclones innovative scv immune system therapy yields positive clinical results in tuberculosis data from phase  clinical trials presented at icaac san mateo calif sep   prnewswirefirstcall via comtex sciclone pharmaceuticals inc nasdaq scln today reported that scv a proprietary compound that enhances the immune system demonstrated the capability to significantly increase the rate at which tr pdf sep   sciclone pharmaceuticals to present at bear stearns healthcare conference tuesday september   at  am et san mateo calif sep   business wire  sciclone pharmaceuticals inc nasdaq scln will present at the bear stearns th annual healthcare conference today at  am eastern time donald r sellers sciclones president and chief executive officer will deliver a presentation which will be webcast live by accessing wwwscicloneco pdf sep   zadaxin improves immune systems detection of colorectal cancer cells zadaxin enhances potential for both therapy and diagnosissan mateo calif sep   prnewswirefirstcall via comtex sciclone pharmaceuticals inc nasdaq scln today reported that treating colorectal cancer cells with zadaxin® significantly increases the expression of a detect pdf sep   sciclones zadaxin in phase  cancer clinical trial in europe  major phase  cancer program targets malignant melanoma  san mateo calif sep   prnewswirefirstcall via comtex sciclone pharmaceuticals inc nasdaq scln announced today that its european union marketing and development partner sigmatau spa has started a large phase  clinical trial in europe usin pdf sep   sciclone pharmaceuticals inc to present at redchip partners investor conference in new york  sept   steve forbes editorinchief of forbes magazine to speak san mateo calif sep   business wire  sciclone pharmaceuticals inc nasdaq scln a biopharmaceutical company whose lead product zadaxin is in phase  hepatitis c trials in the us a phase  hepatitis b trial in japan and a phase  cancer program in europe will present at the redchip partners pdf sep   sciclone to present at bear stearns and redchip new york conferences san mateo calif sep   prnewswirefirstcall via comtex  sciclone pharmaceuticals inc nasdaq scln announced that it will present at bear stearns th annual healthcare conference on tuesday september   at  am eastern daylight time and at redchip partners investor conference on t pdf aug   sciclone pharmaceuticals reports second quarter  results san mateo calif aug   prnewswirefirstcall via comtex  increase in zadaxin® revenues sciclone pharmaceuticals inc nasdaq scln today reported results from the second quarter ended june   revenues from sales of zadaxin the companys lead immune system enhancer pdf jul   sciclone pharmaceuticals to release second quarter  results on august   conference call and webcast scheduled san mateo calif jul   prnewswirefirstcall via comtex sciclone pharmaceuticals nasdaq scln announced that its second quarter  results will be released on tuesday august   before the market opens a conference call and live webcast have been scheduled for  pm eastern  pdf jul   zadaxin produces sustained responses in most difficult to treat hepatitis b patients san mateo calif jul   prnewswirefirstcall via comtex  sciclone pharmaceuticals inc nasdaq scln announced the results of a new study demonstrating that zadaxin® thymalfasin thymosin alpha  helps clear the hepatitis b virus in the most difficult to treat patients those in the immune toler pdf jul   zadaxin increases breast cancer survival rate in nih animal model san mateo calif jul   prnewswirefirstcall via comtex  sciclone pharmaceuticals nasdaq scln today announced the positive results of a breast cancer animal model study using monotherapy zadaxin®® as an immune system enhancer at the week endpoint of the st pdf jun   sciclone pharmaceuticals completes direct offering of common stock various existing and new institutional investors participatesan mateo calif jun   prnewswirefirstcall via comtex sciclone pharmaceuticals inc nasdaq scln today announced that it completed a direct offering of common stock with various existing and new institutional investors sciclone raised gross proceed pdf jun   sciclone pharmaceuticals announces direct offering of common stock san mateo calif jun   prnewswirefirstcall via comtex  sciclone pharmaceuticals inc nasdaq scln today announced that it has priced its direct offering of  shares of its common stock at  per share the shares were offered to various institutional investors under sciclones shelf registration statement that was initi pdf jun   sciclone pharmaceuticals presents at ubs warburgs global specialty pharmaceuticals conference san mateo calif jun   prnewswirefirstcall via comtex  sciclone pharmaceuticals inc nasdaq scln announced that it will present at ubs warburgs global specialty pharmaceuticals conference today june   at  am eastern daylight time donald r sellers sciclones president and chief executive officer will deliver a cor pdf may   sciclone pharmaceuticals announces result of  proxy vote sciclone pharmaceuticals inc nasdaq scln today announced the results of its  proxy vote san mateo calif may   prnewsirefirstcall via comtex  the company is holding its  annual meeting of shareholders at  pm edt  am pdt and a presentation and following qa will be webcast at  pm edt  am pdt the web pdf may   zadaxin® selectively stimulates immune systemrelated genes important in the fight against hepatitis c study presented at the aaslds digestive disease weeksan mateo calif may   prnewswirefirstcall via comtex sciclone pharmaceuticals inc nasdaq scln announced the results of a study demonstrating that zadaxin thymalfasin thymosin alpha  upregulates the expression of multiple immune systemrelated genes  pdf may   sciclone pharmaceuticals to webcast presentation and following qa after annual meeting on may   sciclone pharmaceuticals to webcast presentation and following qa after annual meeting on may   san mateo calif may   business wire  sciclone pharmaceuticals inc nasdaq scln announced that it will webcast a presentation and qa after the  annual meeting of shareholders the annual meeting will be at the hilton garde pdf may   sciclone pharmaceuticals reports first quarter  results  increase in zadaxin® revenues san mateo calif may  prnewswirefirstcall  sciclone pharmaceuticals inc nasdaq scln today reported results from the first quarter ended march   revenues from sales of zadaxin the companys lead immune system enhancer drug were  pdf apr   sciclone sponsors first zadaxin® symposium at international conference for the study of the liver panel of experts discuss zadaxin as a treatment for hepatitis bsan mateo calif apr   prnewswirefirstcall via comtex sciclone pharmaceuticals inc nasdaq scln sponsored a satellite symposium yesterday on the opening day of the joint meetings of the international association for the study of the liver iasl pdf apr   sciclone begins zadaxin® us phase  hepatitis c clinical trials first patients enrolled and receiving treatmentsan mateo calif apr   prnewswirefirstcall via comtex sciclone pharmaceuticals nasdaq scln today announced the first patients in its zadaxin us phase  hepatitis c clinical trials have been enrolled and are receiving treatment the injection of the first pati pdf apr   zadaxin® offers new cancer treatment benefits zadaxin leads to bone marrow recovery after chemotherapy study presented at the american association for cancer research annual meetingsan mateo calif apr   prnewswirefirstcall via comtex sciclone pharmaceuticals nasdaq scln today announced the results of an animal model study demonstrating improved and expa pdf mar   study shows new data supporting zadaxins ability to increase th subset of thelper cells san mateo calif mar   prnewswirefirstcall via comtex data presented at world congress of gastroenterology sciclone pharmaceuticals nasdaq scln today announced the results of a nonclinical study supporting zadaxins observed mechanism of action the study was presented this month at the world congress of gastroenterology in bangko pdf mar   zadaxin in combination therapy has significantly superior sustained response rates compared to interferon monotherapy for hepatitis b san mateo calif mar   prnewswirefirstcall via comtex  for zadaxin in combination therapy versus  for interferon monotherapysciclone pharmaceuticals nasdaq scln today announced that data presented at the world congress of gastroenterology in bangkok thailand this month indicate that after an addition pdf mar   sciclone pharmaceuticals announces positive preliminary data from phase  hepatitis b trial in japan san mateo calif mar   prnewswirefirstcall via comtex  sciclone pharmaceuticals nasdaq scln today announced positive preliminary data from its phase  clinical trial in japan using zadaxin as a monotherapy treatment for hepatitis b preliminary data on approximately onethird of the  patients indicate that after  months of ther pdf feb   sciclone pharmaceuticals inc to present at redchip partners investor conference in boca raton fla on march  san mateo calif feb   business wire  sciclone pharmaceuticals inc nasdaqscln a global biopharmaceutical company that acquires develops and commercializes specialistoriented drugs for treating chronic and lifethreatening diseases will present at the redchip partners investor conference  pdf feb   sciclone pharmaceuticals reports fourth quarter and year end  results san mateo calif feb   prnewswirefirstcall via comtex  sciclone pharmaceuticals nasdaq scln today reported that total revenues for the fourth quarter ended december   from sales of zadaxin® our lead immune system enhancer drug increased  to  compared to  for th pdf dec   zadaxin enters european phase  cancer program san mateo calif dec   prnewswire via comtex sciclone pharmaceuticals nasdaq scln today announced the initiation of a latestage oncology clinical development program in europe for zadaxin sciclones lead immune system enhancer drug the clinical program is being sponsored by sigmatau spa sciclones exclusive partner for zadax pdf sep   sciclone named one of silicon valleys fastest growing technology companies in deloitte  touches fast  program san mateo calif sep   prnewswire  sciclone pharmaceuticals nasdaq scln today announced that the company has been named as a part of deloitte  touches prestigious  technology fast  program for silicon valley a ranking of the  fastest growing technology companies in the area rankings are based on the percentage of growt pdf sep   sciclone pharmaceuticals inc to present at redchip investor conference in new york tuesday sept   at  am et  am ct new yorkbusiness wiresept  sciclone pharmaceuticals inc nasdaqscln a company engaged in drug development and commercialization will present at the redchip investor conference in new york on tuesday sept   the conference will be held at the waldorfastoria hotel  park ave b pdf aug   sciclone receives hepatitis c patent allowance in japan san mateo calif aug  prnewswire  sciclone pharmaceuticals nasdaq scln today announced that the company has received a notice of allowance for patent protection in japan covering the use of zadaxin the companys lead immune system enhancer ise drug for the treatment of hepatitis c the new patent which extends through  also co pdf aug   sciclone completes enrollment for zadaxin® phase  hepatitis b trial in japan san mateo calif aug   prnewswire  sciclone pharmaceuticals nasdaq scln today announced that the company has completed enrollment for its phase  monotherapy hepatitis b trial in japan the second largest pharmaceutical market in the world with zadaxin® the companys lead immune system enhance pdf jul   sciclone pharmaceuticals receives us patent allowance for the use of zadaxin® plus lamivudine and famciclovir to treat hepatitis b san mateo calif jul   prnewswire  sciclone pharmaceuticals nasdaq scln today announced that the us patent and trademark office has issued a notice of allowance for use of the companys lead drug zadaxin® plus lamivudine and famciclovir for the treatment of hepatitis b zadaxin is an immune s pdf jul   sciclones zadaxin® approved as cancer treatment in the philippines san mateo calif jul   prnewswire  sciclone pharmaceuticals nasdaq scln today announced that zadaxin® the companys lead immune system enhancer ise drug has been approved in the philippines as an adjuvant to chemotherapy for the treatment of various cancers zadaxin previously was approved i pdf jul   sciclones zadaxin® approval expanded to include hepatitis c and hepatitis b in mexico san mateo calif jul   prnewswire sciclone pharmaceuticals nasdaq scln today announced that the companys immune system enhancer zadaxin® has received expanded indications in mexico zadaxin may now be marketed for the treatment of hepatitis c and hepatitis b as well as for use as an influenza  pdf jun   sciclone pharmaceuticals inc to present at redchip investor conference thursday june   at  pm et   pm pt portland orebusiness wirejune  sciclone pharmaceuticals inc nasdaqscln a developer of drugs for chronic diseases will present at the redchip™ investor conference in portland ore on thursday june   at  pm eastern time  pm pacific time this event is b pdf may   sciclone pharmaceuticals to offer webcast of presentation and qa following annual meeting on thursday may   san mateo califbusiness wiremay  sciclone pharmaceuticals nasdaqscln today announced that it will webcast the annual presentation and qa following the  annual meeting of stockholders on thursday may  at  am pacific time the meeting will be held at the hilton garden inn at  bridgepointe circle san mateo ca pdf mar   sciclone appoints richard a waldron as chief financial officer san mateo ca march    sciclone pharmaceuticals nasdaq scln today named richard a waldron as chief financial officer in addition to his responsibilities as chief financial officer mr waldron will also be extensively involved in corporate development and serve as a member of sciclones executive staff sciclone pharmaceuticals h pdf feb   sciclones zadaxin® is able to increase antitumor effects while markedly reducing the toxicity of chemotherapy in treating melanoma colorectal cancer and nsclc san mateo ca february    sciclone pharmaceuticals nasdaq scln today announced at the roth capital partners th annual growth stock conference that a review published in the peerreviewed journal international journal of immunopharmacology volume  pp  discusses that zadaxin® sciclone pdf feb   sciclone pharmaceuticals reports  results san mateo ca february    sciclone pharmaceuticals nasdaq scln today announced results for the fourth quarter and year ended december   for the year ended december   sciclone reported total revenues increased  to  based entirely on sales of zadaxin® pdf feb   sciclones zadaxin® approved in india for hepatitis b san mateo ca february    sciclone pharmaceuticals nasdaq scln today announced that its lead drug zadaxin® has been approved in india for the treatment of hepatitis b sciclone reported that commercial introduction of zadaxin into the indian market could begin as early as the second quarter of this y pdf jan   sciclone pharmaceuticals starts pivotal us phase  hepatitis c program with zadaxin plus pegylated alfa interferon san mateo ca january    sciclone pharmaceuticals nasdaq scln today announced that it has initiated its pivotal us phase  hepatitis c clinical program for zadaxin® in combination with pegasys® pegylated interferon alfaa sciclones pivotal phase  hepatitis c program its larges pdf jan   sciclone initiates us phase  liver cancer trial with zadaxin® plus radio frequency ablation san mateo ca january    sciclone pharmaceuticals nasdaq scln today announced the initiation of a us phase  study in patients with hepatocellular carcinoma evaluating the effectiveness of zadaxin® the companys immune system enhancer in combi pdf jan   sciclone named one of  best health care websites san mateo ca january    sciclone pharmaceuticals nasdaq scln said its website  wwwsciclonecom  has been named one of the  best sites in the health care industry by med ad news a leading trade publication for healthcare marketing and advertising professionals sciclone was chosen as on pdf dec   sciclone pharmaceuticals completes  million financing san mateo ca december    sciclone pharmaceuticals inc nasdaq scln today announced the purchase by an investment affiliate of ubs ag one of the worlds five largest financial institutions of a  million senior unsecured convertible note sciclone also received  for the right to pdf dec   sciclone pharmaceuticals receives second european patent for the treatment of hepatitis c with zadaxin® san mateo ca december    sciclone pharmaceuticals nasdaq scln today announced that the european patent office has allowed the company a patent covering the use of zadaxin® for the treatment of hepatitis c in nonresponders a nonresponder is a  pdf dec   sciclone comments on product revenue expectations san mateo ca december    sciclone pharmaceuticals nasdaq scln today announced updated expectations for product revenues in the fourth quarter of  the company now expects that product sales for the fourth quarter of  will fall below those of the years third quar pdf nov   sciclone pharmaceuticals initiates zadaxin® malignant melanoma clinical study in australia san mateo ca november    sciclone pharmaceuticals nasdaq scln announced that a new zadaxin® clinical study for malignant melanoma the deadliest form of skin cancer and one of the most rapidly increasing types of cancer worldwide has been initiated in australia  pdf nov   sciclone pharmaceuticals named one of the  fastest growing technology companies in north america san mateo ca november    sciclone pharmaceuticals nasdaq scln today announced that the company has been recognized as part of the deloitte  touche technology fast  award in year  for the  fastest growing technology companies in the us and canada rankings are based on fivey pdf nov   sciclone pharmaceuticals announces successful reformulation of cpx for expanded phase  studies in cystic fibrosis patients san mateo ca november    sciclone pharmaceuticals nasdaq scln today announced at the cystic fibrosis foundations cff th annual north american cystic fibrosis conference in baltimore that cpx the companys lead proteinrepair therapy for cystic fibrosis cf has been successfully ref pdf nov   sciclone pharmaceuticals receives  new product technology development award from city of san mateo in silicon valley ca san mateo ca november    sciclone pharmaceuticals nasdaq scln announced today that it has received the  new producttechnology development award from the chamber of commerce of the city of san mateo ca in its annual outstanding business awards program sciclone is the only biopharmac pdf oct   new study helps explain the fundamental role of sciclones zadaxin® in the successful treatment of chronic hepatitis b san mateo ca october    sciclone pharmaceuticals nasdaq scln announced that a new study presented today at the st annual meeting of the american association for the study of liver diseases aasld in dallas further confirms zadaxin®s powerful ability to activate tcells disease fighting white blood cells and helps explain  pdf oct   sciclone pharmaceuticals completes north american patent position for zadaxin® in hepatitis c psan mateo ca october    sciclone pharmaceuticals nasdaq scln announced today that it has received an issued patent in canada for the use of the companys lead drug zadaxin® for the treatment of hepatitis c one of the worlds most common bloodborne infectious diseases the new canadian patent complements the companys previo pdf oct   sciclone pharmaceuticals reports third quarter results san mateo ca october    sciclone pharmaceuticals nasdaq scln a global specialty biopharmaceutical company announced that it has achieved breakeven net profit status for the third quarter ended september   one quarter ahead of its stated goal of profitable operations by yearend revenues for the third quarter o pdf sep   sciclone strengthens latin american position for zadaxin in hepatitis c san mateo ca september    sciclone pharmaceuticals nasdaq scln announced today that it has received an issued patent in mexico for the use of the companys lead drug zadaxin for the treatment of hepatitis c sciclone also announced that peru has expanded zadaxins approval to include the treatment of hepatitis c as well as the p pdf sep   sciclone pharmaceuticals named one of silicon valleys  fastest growing technology companies san mateo ca september    sciclone pharmaceuticals nasdaq scln today announced that it has been recognized as part of deloitte  touches prestigious fast  for  a ranking of the  fastest growing technology companies in silicon valley rankings are based on the percentage of growth in revenues from sc pdf aug   sciclone pharmaceuticals expands board of directors san mateo ca august    sciclone pharmaceuticals nasdaq scln today announced that it has appointed jon s saxe esq and dean s woodman to its board of directors mr saxe was president of protein design labs inc nasdaq pdli from  to early and currently serves as a director pdf aug   sciclones zadaxin® receives expanded approval in argentina for hepatitis b and hepatitis c san mateo ca august    sciclone pharmaceuticals nasdaq scln today announced that zadaxin® its lead immunotherapy has received expanded marketing approval in argentina for the treatment of both hepatitis b and hepatitis c zadaxin previously was approved in argentina as a vaccine adjuvant for patients with weakened immune syst pdf aug   sciclone pharmaceuticals launches zadaxin® in mexico san mateo ca august    sciclone pharmaceuticals nasdaq scln today announced that it has begun marketing and distributing zadaxin® its lead immunotherapy in mexico zadaxin is also approved for sale in other latin american markets including argentina venezuela and peruzadaxin marketing and distribution in latin am pdf jul   sciclones zadaxin® prevents formation of lung tumors in nih study san mateo ca july    sciclone pharmaceuticals nasdaq scln announced today the publication of results of a national institutes of health nih preclinical study indicating that its zadaxin® immunotherapy may decrease formation of lung tumors the study published in the peerreviewed journal cancer letters volume  pdf jul   sciclone pharmaceuticals announces record revenues for the second quarter of  san mateo ca july    sciclone pharmaceuticals nasdaq scln a global specialty biopharmaceutical company targeting cancer infectious diseases and cystic fibrosis today announced record results for the second quarter ended june  revenues for the second quarter of  from sales of zadaxin® pdf jun   sciclone pharmaceuticals granted us patent for the use of zadaxin® to treat heptatitis b san mateo ca june    sciclone pharmaceuticals nasdaq scln today announced that the us patent and trademark office has issued a notice of allowance for use of the companys lead drug zadaxinò for the treatment of hepatitis b zadaxin is the safe synthetic preparation of thymosin alpha  pdf may   sciclones zadaxin® commercially available in italy san mateo ca may    sciclone pharmaceuticals nasdaq scln today announced at the ubs warburg global specialty pharmaceuticals conference that zadaxin the companys lead immunotherapy is now commercially available in italy this represents the first commercial launch of zadaxin in a europe pdf may   new study shows improvement in quality of life for chemotherapy patients receiving sciclones zadaxin® san mateo ca may    sciclone pharmaceuticals nasdaq scln announced that in a study presented today in a poster session at the annual meeting of the american society of clinical oncology asco independent investigators concluded that zadaxin sciclones lead immunotherapy can significant pdf may   sciclone pharmaceuticals granted us patent for dax a promising cystic fibrosis drug candidate san mateo ca may   sciclone pharmaceuticals nasdaq scln today announced at the hc wainwright  co inc emerging growth stock conference that the us patent  trademark office has granted the company an important patent concerning the use of dax diallylcyclohexylxanthine as a tr pdf apr   sciclones  first quarter zadaxin® sales increase  san mateo ca april    sciclone pharmaceuticals nasdaq scln today announced that first quarter  sales of zadaxin the companys lead immunotherapy were  an increase of  over first quarter  zadaxin sales of  for the first quarter of  the net loss of  decreased  when compare pdf apr   sciclones zadaxin® approved in south korea san mateo ca april    sciclone pharmaceuticals nasdaq scln today announced the approval of zadaxin its lead immunotherapy in south korea one of the worlds largest pharmaceutical markets the south korean approval is for use of zadaxin as an influenza vaccine adjuvant by individuals wit pdf apr   zadaxin® plus chemotherapy shows promise for improved survival in advanced skin cancer san mateo ca april    sciclone pharmaceuticals nasdaq scln announced today that a study published in the peerreviewed journal melanoma research volume  issue  april  suggests that zadaxinò sciclones lead immunotherapy increases the effectiveness of chemotherapy for metastatic pdf mar   fda grants orphan drug status to sciclones zadaxin® for the treatment of liver cancer san mateo ca march    sciclone pharmaceuticals nasdaq scln today announced that the us food and drug administration fda has granted orphan drug status to zadaxin® sciclones lead immunotherapy for the treatment of hepatocellular carcinoma pdf mar   sciclone receives three new zadaxin® marketing approvals san mateo ca march    sciclone pharmaceuticals nasdaq scln today announced that zadaxin the companys lead immunotherapy has been approved for marketing in thailand laos and malta zadaxin now is approved for marketing in  countries principally for treatment of hepatitis b and hepatit pdf mar   sciclone and sigmatau sign expanded zadaxin® hepatitis c and cancer partnership for europe rome italy and san mateo ca march    sciclone pharmaceuticals nasdaq scln and sigmatau spa the leading researchbased italian pharmaceutical company announced today they have signed an expanded development and marketing partnership for zadaxinò sciclones host immune system enhance pdf mar   new study shows zadaxins dual role in immune recognition of and response to cancer and infection san mateo ca march    sciclone pharmaceuticals nasdaq scln announced today that a study published in the peerreviewed european journal of immunology march  volume  issue  shows that zadaxin® thymosin alpha  directly increases the immune sys pdf feb   sciclone awarded  grant to study new immunomodulator for tuberculosis san mateo ca february    sciclone pharmaceuticals nasdaq scln announced today at the th annual cruttenden roth growth stock conference that it has been awarded a  grant to study scv the companys new immunomodulator as a potential treatment for tuberculosis tb the most co pdf feb   sciclone pharmaceuticals moves forward with development of cpx for cystic fibrosis san mateo ca february    sciclone pharmaceuticals nasdaq scln today announced plans to move forward with the next stage of its phase  development program for cpx a novel prt protein repair therapy for cystic fibrosis cf sciclone working closely with scientists and clinical investig pdf feb   sciclone pharmaceuticals reports  results san mateo ca february    sciclone pharmaceuticals nasdaq scln today announced results for the fourth quarter and year ended december  for the year the company reported total revenue of  a  increase over the  reported for  sales of zadaxinò the companys host immune system enhancer  pdf jan   sciclone initiates us phase  study of zadaxin® plus lamivudine for hepatitis b san mateo ca january    sciclone pharmaceuticals nasdaq scln today announced the start of a us phase  hepatitis b study using zadaxin the companys host immune system enhancer hise in combination with lamivudine an fdaapproved nucleoside analogue the study conducted at loyola u pdf jan   sciclone pharmaceuticals expands capital base san mateo ca january    sciclone pharmaceuticals nasdaq scln today announced the completion of a  private placement with its largest institutional shareholder the brown simpson strategic growth funds the newly acquired funds will be directed toward the distribution of zadaxin pdf nov   sciclone appoints two new regional managing directors to expand zaxadin® sales in latin america and the middle east san mateo ca november    sciclone pharmaceuticals nasdaq scln announced the appointment of craig r olson as regional managing director latin america and kenneth r cowan as regional managing director middle east for the companys international subsidiary sciclone pharmaceuticals international ltd olson and cowan become sciclone pdf email alerts email alerts snapshot snapshot rss rss print print email email search search   sciclone pharmaceuticals inc all rights reserved please read our disclaimer terms of use  notes regarding forward looking statements 。。